 
 
 
     
 
 
 
 
 
 
Official Title :  A Randomized, Double -Blind, Placebo - and Active -Controlled Study to Determine the 
Efficacy and Safety of CL -108 5 mg (hydrocodone 5 mg/acetaminophen 325 mg/ promethazine 12.5 mg) as 
a Treatment for Moderate -to-Severe Acute Pain and the Prevention of Opioid -Induced Nausea and Vomiting 
(OINV) following Orthopedic Surgery  
 
NCT Number : NCT 03657810  
 
Applicant/MAH:  Charleston Laboratories Inc. 
 
Version Date : 17 August 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
16. APPENDICES 
 
16.1 Study Information 
 
16.1.1 Protocol and Protocol Amendments 
Protocol Amendment 02 Version 3.0 dated 17 August 2017 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 1 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
&KDUOHVWRQ/DERUDWRULHV,QF
3URWRFRO1XPEHU&/&7&OLQLFDO6WXG\5HSRUW)LQDO
1RY
&RQILGHQWLDO 3DJHRIBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBPI
PI
PI
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 2 of 86 
 TABLE OF CONTENTS  
1 SYNOPSIS  ................................................................................................................................................................... 6  
1.1 TITLE ...................................................................................................................................................................... 6  
1.2 OBJECTIVES  ............................................................................................................................................................ 6  
1.3 STUDY DESI GN ........................................................................................................................................................ 6  
1.4 ENDPOINTS  ............................................................................................................................................................. 9  
1.4.1  Co-Primary Endpoints  ............................................................................................................................. 9  
1.4.2  Key Secondary Endpoints  ........................................................................................................................ 9  
1.5 SETTING AND PATIENTS  .......................................................................................................................................... 9  
1.6 STUDY TREATMENTS  ............................................................................................................................................ 10 
1.7 SAMPLE SIZE ......................................................................................................................................................... 10 
1.8 STUDY  FLOW  CHART  ...................................................................................................................................... 11 
2 BACKGROUND AND RATIO NALE FOR THE STUDY  .................................................................................... 12 
3 OBJECTIVES OF THE ST UDY  ............................................................................................................................. 13 
4 TRIAL DESIGN  ........................................................................................................................................................ 13 
4.1 VISIT 1 .................................................................................................................................................................. 13 
4.2 VISIT 2 .................................................................................................................................................................. 14 
4.3 OUTPATIENT PHASE (DAYS 3-7) ........................................................................................................................... 17 
4.4 VISIT 3 .................................................................................................................................................................. 17 
5 PATIENT SELECTION AN D WITHDRAWAL  ................................................................................................... 18 
5.1 INCLUSION CRITERIA  ............................................................................................................................................ 18 
5.2 EXCLUSION CRITERIA  ........................................................................................................................................... 19 
5.3 USE IN FEMALES  ................................................................................................................................................... 21 
5.4 PREGNANCY OCCURRING DURING A CLINICAL TRIAL .......................................................................................... 21 
5.5 USE OF SUPPLEMENTAL (RESCUE ) MEDICATION  .................................................................................................. 21 
5.6 WITHDRAWAL  ....................................................................................................................................................... 22 
5.6.1  Investigator‚Äôs Reasons for Patient Withdrawal  ...................................................................................... 23 
5.6.2  Handling of Withdrawals  ....................................................................................................................... 24 
6 STUDY PROCEDURES  ........................................................................................................................................... 24 
6.1 EVALUATIONS OF SAFETY AND ELIGIBILITY  ......................................................................................................... 24 
6.2 EVALUATIONS OF EFFICACY AND SAFETY (SEE APPENDICES FOR SAMPLE INDICES ) ............................................ 25 
6.2.1  Categorical Pain Intensity Scale (PI- CAT)  ............................................................................................ 25 
6.2.2  Numerical Pain Intensity Rating Scale (PI -NRS)  .................................................................................. 26 
6.2.3  Nausea Scale (NS)  ................................................................................................................................. 26 
6.2.4  Vomiting Frequency Scale (VFS)  .......................................................................................................... 26 
6.2.5  Opioid Symptom Scales (OSS) (from the Symptom Distress Scale)4 ................................................... 26 
6.2.6  Uses of Supplemental (Rescue) Analgesic Medication  ......................................................................... 27 
6.2.7  Uses of Anti -emetic (Rescue) Medication  ............................................................................................. 27 
6.2.8  Patient Reports of Adverse Events (Elicited an d Volunteered)  ............................................................. 27 
6.3 STUDY CONDUCT  .................................................................................................................................................. 27 
6.3.1  Pre-Screening Procedures  ...................................................................................................................... 27 
6.3.2  Screening Procedures (Visit 1) .............................................................................................................. 28 
6.3.3  Surgery Day (Visit 2)  ............................................................................................................................. 30 
6.3.4  Post-Surgical Eligibility Assessments and Dosing  ................................................................................ 32 
6.3.5  Study Times Initial 12 Hours Post- Initial Dose  ..................................................................................... 34 
6.3.6  Study Times: 12 Hours Post -Initial Dose th rough 48 Hours  .................................................................. 35 
6.3.7  Study Time: Additional Assessments at 24 hours (¬±15 Minutes)  .......................................................... 35 
6.3.8  Study Time: 48 hours (¬±15 Minutes)  ..................................................................................................... 36 
6.3.9  Outpatient Activities:  Day 3 through Day 7  ......................................................................................... 37 
6.3.10  Follow -Up Telephone Call:  approximately 24 hours after discharge (+2 days, to account for 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 3 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 3 of 86 
 weekends)  ............................................................................................................................................................. 37 
6.3.11  Follow -Up Visit 3 on Day 8 (¬± 2 days) .................................................................................................. 38 
6.4 CONCOMITANT THERAPY  ...................................................................................................................................... 38 
6.5 ASSIGNMENT OF NUMBERS  ................................................................................................................................... 38 
6.6 TREATMENT  .......................................................................................................................................................... 39 
6.7 CLINICAL ADVERSE EVENTS  ................................................................................................................................. 39 
6.8 RISKS/PRECAUTIONS  ............................................................................................................................................. 39 
6.9 OVERDOSAGE  ....................................................................................................................................................... 39 
7 DATA COLLECTION AND ANALY SIS ............................................................................................................... 40 
7.1 RECORDING OF DATA ........................................................................................................................................... 40 
7.2 CONTROL METHODS  ............................................................................................................................................. 40 
7.3 SAFETY ASSESSMENTS  .......................................................................................................................................... 40 
7.4 STATISTICAL ANALYSIS  ........................................................................................................................................ 41 
7.4.1  Primary Hypotheses  ............................................................................................................................... 41 
7.4.2 Sample Size Justification  ....................................................................................................................... 42 
7.4.3  Key Secondary Endpoints  ...................................................................................................................... 42 
7.4.4  Labeling Endpoints  ................................................................................................................................ 43 
7.4.5  Study Populations  .................................................................................................................................. 44 
7.4.6  Predefined Subgroups  ............................................................................................................................ 44 
7.4.7  Missing Data Conventions  ..................................................................................................................... 44 
7.4.8  Use of Supplemental Medication  ........................................................................................................... 44 
7.4.9  Statistical Analysis  ................................................................................................................................. 45 
7.4.10  Descriptive Statistics: ............................................................................................................................. 45 
7.4.11  Analysis of the OINV Co -Primary Endpoint:  ........................................................................................ 45 
7.4.12  Analysis of Analgesia Co -Primary Endpoint:  ........................................................................................ 45 
7.4.13  Sensitivity Analysis of Primary Endpoints  ............................................................................................ 45 
7.4.14  Analyses of Key Secondary Endpoints:  ................................................................................................. 46 
7.4.15  Statistical Significance:  .......................................................................................................................... 46 
7.4.16  Safety  ..................................................................................................................................................... 46 
7.4.17  Interim Analyses  .................................................................................................................................... 46 
7.4.18  Protocol Deviations  ................................................................................................................................ 47 
8 CLINICAL SUPPLIES  ............................................................................................................................................. 47 
8.1 PACKAGING  .......................................................................................................................................................... 47 
8.2 LABEL  ................................................................................................................................................................... 47 
9 INVESTIGATOR OBL IGATIONS  ......................................................................................................................... 48 
9.1 ADVERSE EVENT REPORTING OBLIGATIONS  ......................................................................................................... 48 
9.1.1  Definition of an Adverse Event  ............................................................................................................. 48 
9.1.2  Definition of a Serious Adverse Event (SAE)  ....................................................................................... 49 
9.1.3  Recording and Documenting Adverse Events  ....................................................................................... 50 
9.1.4  Intensity of Adverse Events  ................................................................................................................... 50 
9.1.5  Relationship to Study Medication  .......................................................................................................... 51 
9.1.6  Therapeutic Failure as an Adverse Event  ............................................................................................... 51 
9.1.7  Treatment Period  .................................................................................................................................... 52 
9.1.8  Investigator Report of a Serious Adverse Event  .................................................................................... 52 
9.1.9  Other Investigations  ............................................................................................................................... 53 
9.1.10  Ethics Committee Notification ............................................................................................................... 53 
9.1.11  Post-study Serious Adverse Events  ........................................................................................................ 53 
9.1.12  Regulatory Aspects  ................................................................................................................................ 53 
9.2 DRUG ACCOUNTABILITY ....................................................................................................................................... 53 
9.2.1  Storage of Investigational Drug  ............................................................................................................. 53 
9.2.2  Receipt of Drug Shipment  ..................................................................................................................... 53 
9.2.3  Materials Control ................................................................................................................................... 54 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 4 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 4 of 86 
 9.2.4  Return of Drug to Sponsor  ..................................................................................................................... 54 
9.3 DEVIATIONS FROM PROTOCOL  .............................................................................................................................. 54 
9.4 DISCLOSURE OF DATA .......................................................................................................................................... 54 
9.4.1  Confidentiality  ....................................................................................................................................... 54 
9.4.2  Publication  ............................................................................................................................................. 55 
9.5 STUDY RECORDS AND SOURCE DOCUMENTS  ........................................................................................................ 55 
9.6 INVESTIGATOR DOCUMENTATION  ......................................................................................................................... 56 
9.6.1  Patient Consent  ...................................................................................................................................... 56 
9.6.2  Ethics Committee Review  ...................................................................................................................... 56 
9.6.3  Curriculum Vitae and FDA Form 1572  ................................................................................................. 57 
9.6.4  Financial Disclosure ............................................................................................................................... 57 
9.6.5  Tax ID No. and Form W -9 ..................................................................................................................... 57 
9.6.6  Laboratory Certification and Normal Values  ......................................................................................... 57 
9.6.7  Final Report to the IRB  .......................................................................................................................... 57 
10 TERMINATION OF STUDY  .................................................................................................................................. 57 
11 INVESTIGATOR'S PROTO COL AGREEMENT  ................................................................................................ 57 
12 REFERENCES  .......................................................................................................................................................... 58 
13 APPENDICES  ........................................................................................................................................................... 59 
13.1 APPENDIX 1. ANALGESIC RATING  SCALES  ....................................................................................................... 59 
13.2 APPENDIX 2: NAUSEA /VOMITING RATING SCALES  .......................................................................................... 60 
13.3 APPENDIX 3: OPIOID SYMPTOMS SCALES (OSS)  .............................................................................................. 61 
13.4 APPENDIX 4.  NAUSEA PRONE QUESTIONNAIRE (CALLED ‚ÄúHEALTH QUESTIONNAIRE ‚Äù IN THE  CRF)  ............... 62 
14 INVESTIGATOR'S PROTO COL AGREEMENT  ................................................................................................ 69 
15 PROTOCOL AMENDMENT 1 : TABLE OF CHANGES  .................................................................................... 70 
16 PROTOCOL AMENDMENT 2: TABLE O F CHANGES  .................................................................................... 83 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 5 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 5 of 86 
 List of Abbreviations 
 
ÀöF degrees Fah r enheit  
APAP  acetaminophen  
BO
CF baseline ob servation carried forward  
CL Charleston Labor atories, Inc.  
CL-108 hydrocodone 7.5 mg/APAP 325 mg/promethazine 12.5 mg 
CL-108 5 mg  hydrocodone  5 mg/APAP 325 mg/promethazine 12.5 mg 
CRO  Contract Research  Organiz ation  
eCRF  Electronic CRF  
ESAS  Edmonton Symptom  Assessment Scales 
DMC  Data Monitor ing Committee  
FDA  Food and Drug Adm inistration 
GCP  Good Clinic al Practice  
HC/APAP  hydrocodone 5 m g/APAP 325 mg 
HCG human chorionic gonadotropin  
hr hour 
ICF informed c
onse nt form 
IRB Institutional Review Board  
ITT intent- to-treat 
LOC
F last observa tion carried forward  
MedDRA  Medical Dic tionary for Regulatory Activities  
mg milligram 
mo month 
No
rco¬Æ hydrocodone 5 mg/APAP 325 mg 
NS Nausea Scale  
NNT  N
umber-neede d to treat 
NPQ Nausea -Prone Q uestionnaire 
OINV  opioid-induced naus ea and vomiting 
OSS Opioid Symptom s Scales  
PI-CAT  categoric al pain intensity rating scale  
PI-NRS numerical  pai n intensity rating scale  
PID pain intensit y difference 
SAE  serious ad verse event  
SAP statistical an alysis plan  
SPID 24 summed pain intensity differences over 24 hours 
SPID 48 summed pain intensity differences over 48 hours 
SDS Symptoms Dis tress S cale 
US United State s 
VFS Vomiting Fr equency Scale 
WHO- DD World Hea lth Organization -Drug Dictionary  
WOCF  Worst observa tion carried forward 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 6 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 6  of 86 
 1 SYNOPSIS  
1.1 Title  
A Ra ndom
ized, D
ouble -Blind, Placebo-  and Active -Controlled Study to Determine  the Efficacy  and 
Safety of CL -108 5 mg (hydrocodone 5 mg/acetaminophen 325 mg/ promethazine 12.5 mg)  as a 
Treatment for Moderate -to-Severe Acute Pain and the Prevention of Opioid- Induced Nausea and 
Vomiting (OINV)  following Orthopedic Surgery. 
1.2 Objectives 
To determine  the 
analgesic efficacy  of CL -108 5 mg by comparison with  placebo  and the anti -emetic 
efficacy of CL -108 5 mg by comparison with  hydrocodone 5 mg/acetaminophen 325 mg 
(HC/ APAP ).  
1.3 Study design 
This is a  phase 
3, randomi zed, double-blind, multiple-dose , multi- site controlled study of CL -108  5 
mg (hydrocodone 5 mg/APAP 325 mg /promethazine 12.5 mg)  compared to placebo and to a 
standard formulation of hydrocodone 5 mg/APAP 325 mg ( Norco¬Æ) in patients  with moderate- to-
severe pain follow ing unilateral  first metatarsal bunionectomy (with osteotomy and internal fixation) 
without collateral procedures.    
Adult s 18 years  at time of co nsent  of age and older who have a bunion on the foot which they want 
removed an d who are possibly at risk for OINV will have  a Screening V isit (Visit 1 ) when a foot x -
ray will be obtained (if not in possession of a foot x -ray within the past 6 months) and reviewed by 
the surgeon (between Visit 1 and Visit 2 prior to surgery).  Admissi on criteria will be reviewed, a 
screening physical examination will be performed , urine will be colle cted (for drug screening and 
cotinine on all p atients ) and pregnancy testing (for all female patients  regardless of childbearing 
potential).  
The medical history will be obtained, including a Nausea -Prone Questio nnaire (NPQ). This 
instrument was developed for  previous Phase 3 studies to increase assay  sensitivity  by enriching the 
study sample with patients  who, by history, are assumed to be at risk of developing OINV according 
to accepted criteria (e.g., by a history of previous OINV, nausea/vomiting after a surgical procedure 
or operation, exposure to an opioid, or motion sickness ).1-3,6-8  patients  whom the Investigators  
consider possibly at risk of OINV according to their responses on the  NPQ will b e scheduled for 
surgery within 3 months. Urine pregnancy tests will be performed on all female patients  and urine drug 
 screening tests and 
urine cotinine test will be performed on all patients  prior to surgery at Visit 2 . After sed ation  
(midazolam and/or propofol ) is achieved, regional anesthesia will be established with a popliteal 
sciatic nerve block (PSB), after  which patients  will undergo primary, unilateral, first metatarsal 
bunionectomy s urgery  (osteotomy and internal fixation) without collateral procedures. Surgery will 
be performed under regional anesthesia and propofol sedation. If the PSB is not sufficient to provide 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 7 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Pag e 7 of 86 
 adequate anesthesia, a standard Mayo block may be established. Prophy lactic or  post- op erative anti -
emetic or analgesic medications other than protocol -defined  medications will not be permitted  (see 
Section 5.2). 
After surgery the regional anesthesia will be continued via a continuous anesthetic  infusion until 
ap
proximately 3 am of the morning after surgery  (see Section 6.3.3) . Supplementary analgesic 
medication (IV or IM ketorolac) may be administered as needed for breakthrough pain. Patients  will 
be observed in the research center for up to 9 hours after the PSB is  disconti nued to observe if they 
report the presence of moderate or severe pain by a rating of 2 or 3 on a  0-3 categorical pain intensity 
scale (PI -CAT) .  
Baseline  pain intensity must  be confirm ed b y a rating ‚â•4 on a 0- 10 numerical rating sca le (PI -NRS) 
in order to be eligible for randomization. Temperature ( aural ), pulse, res
 piratory rate, systolic and diastolic blood pressure ( semi -recumbent  
for 5 minutes) will be obtained at Baseline.   To determine if  nausea and vomit
 ing or  other symptoms associated with opioids  (e.g., drowsiness, 
dizziness, ability to concentrate, itch, constipation) are present before exposure to study medication, 
patients  will then complete these measures of patient -reported outcomes: 
‚Ä¢ Nausea Scale (NS) , a binary  scal e to assess the presence/absence of nausea 
‚Ä¢ Vomiting Frequency Scale (VFS), a 0 -to-3 ordinal scale to assess the occurrence of vomiting  
over the past hour ( not at all, 1 time, 2  times, 3 or more times ) 
‚Ä¢ Opioid Symptoms Scales (OSS) , derived f rom the Symptom Distress Scale s,4 to assess the 
presence and severity of other opioid- related side effects  (e.g., drowsiness, dizziness, ability to 
concentrate, itch, constipatio n) 
Qualifying patients  (n=330) will be  assigned a randomization number and randomized under 
double- blind conditions to one of the three treatment groups:   CL-108 5 mg, hydrocodone 5 
mg/APAP 325 mg  (HC/APAP ), or placebo.  All r andomized patients  will remain at the research 
site for the primary initial 48-hour treatment observation period when the same assigned study 
medication will be administered  on schedule for a total of 10 doses.  Subjects should be awoken  
for dosing, as needed to remain on the dosing schedule. 
In the Clinic Diary, a fter baseli ne assessments, p ain intensity ( on the PI -NRS ) and nausea (on the 
NS) will be assessed  every 30 minutes over the next 12 hours (while awake) . 
Beginning at 1 hour through 12 hours after the f irst dos e, the V FS will be  completed hourly to assess 
the occurrence and frequency of retching and/or vomiting. 
After 12 hours, the patient will complete  the PI -N RS, NS and V FS every hour (if  awake) until 48 
hours. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 8 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 8 of 86 
 To provide evaluations of other opioid- related si d e effects after multiple doses of study medication  
over the first and second day of therapy , patients  will repeat the OSS at 24 hours and 48 hours. 
In additi on to these actively solicited assessment s of nausea, vomiting and other opioid side effects, 
the Study Coordinator will also observe the patient ‚Äôs status on an hourly basis throughout the entire 
initial 48-hour treatment observation period in the clinic .   At these hourly intervals during the day 
and at night (if the patient is awake) p atients  will also be asked how they are feeling and  to report 
any other  adverse events .  The Investigator will ra te the severity  of all side effects on a 3-category  
severity  scale (mild, moderate, severe) and determine relationship of the adverse event to study 
drug.  These data  will be documented  on the  AE p age of the eCRF .  Subjects should be awoken for 
dosing, as needed to remain on the dosing schedule. 
 
Temperature ( aural ), pulse, respiratory rate, systolic and diastolic blood pressure ( semi -recumb ent 
for 5 minutes) will be obtained every 6 hours (if awake) until 24 hours post-dosing and at 48 hours.  
Patients  may take  supplemen tary (rescue) analgesic medication , ibuprofen 400 mg , as needed at any  
time according to label directions  (every 4 -6 hours, up to 2,400 mg over 24 hours), but they will be 
encouraged to wait at least 2 hours after the initial dose of study medication, if possible, to allow 
time for evaluation of only the study medication.  
Anti-emetic (rescue) med ication (prescribed by the Investigator according to standard clinical 
practice) is permitted any time after the initial dose of study medicatio n.   
No other post- operative medications are permitted.  
Throughout the entire in itial 48-hour treatment observation period, scheduled dosing of s tudy 
medication  will not be interrupted by  use(s) of rescue medication.  As a result,  all patients  will 
receive 5 doses of study medication during each 24 -hour period ( for a total of 10 doses  over 48 
hours).      At the completion of the 48-hour assessments , patients  will 
 be discharged  as outpatients  for D ays 3 -7 
of the study.  They will receive instructions  for routine post -op care and for  self-dosing with the 
same assigned study  medication as needed for pain every 4- 6 hours (for a maximum of 6 doses in a 
24-hour period), documenting the date and time of each dosing with study medication in an 
Outpatient Diary.    
Patients  will also use the Outpatient Diary to record the date and time of taking (rescue) 
supplementa
l analgesic medication (ibuprofen 400 mg) and/or prescribed anti -emetic medication  and 
any adverse events they experienced over the past 24 hours.   Approximately 24 hours after the patient is discharged from the clinic after Visit 2, the  Study 
Coordina
tor will telephone the patient to inquire about his/her post -op status, adverse events, uses of 
study medication and (rescue) supplemental medications, and use of the  Diary and to confirm the 
follow-up appointment. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 9 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 9 of 86 
 Approximately 8 (¬± 2) days  after surgery, patients  will return to the clinic for Visit 3 , when the 
patient‚Äôs Outpatient Diary, use of study medication and supplemental  medications , and all adverse 
events will be reviewed. Vital signs will be measured for all patients , and a third urine cotinine test 
will be perform ed on all patients and urine pregnancy test will be performed on all female patients . 
All patients  will then be discharged from the study.  Routine post -op care will be  provided according 
to standard clinical practice, with telephone follow -up for any  ongoing side effects until resolution  or 
stabilization . 
1.4 Endpoints 
1.4.1 Co-Primary En dpoints 
‚Ä¢ Occurrence of opioid-induced nausea and vomiting (OINV*) over 48 hours, 
comparing  CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg  
* OINV defined as a 2-component endpoint:  any vomiting or use of anti- emetic 
medication (indicative of nausea)  
‚Ä¢ Relief of moderate to severe acute pain over 48 hours (SPID 48), comparing CL -108 5 
mg to placeb o 
1.4.2 Key Secondary Endpoints  
1) Absence of any nausea, any vomiti ng, or any use of anti -emetic medication over 48 
hours (complete absence of OINV), comparing CL -108 5 mg  to hydrocodone 5 
mg/APAP 325 mg 
2) Percentage of patients  with out an y vomiting  over 48 hours, comparing  CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 mg  
3) Percentage of patients with out any nau sea  over 48 hour s, comparing CL -108 5 mg to 
hydrocodone 5 mg/APAP 325 mg  
4) Percentage of patients without any nausea  or vomiting 48 hours, comparing       CL -108 
5 mg to hydrocodone 5 mg/APAP 325 mg  
1.5 Setting and Patients  
Approximat
ely t hree hundred and  thirty (330) patients  undergoing a primary, unilateral 
metatarsal bunionectomy  (osteotomy and internal fixation without collateral procedures) will be 
randomized to study medication at different research centers in the US.  
Males and non- pregnant, non-lactating females aged 18 years and older that experience moderate 
or severe acute pain will be eligible to participate  in the randomized, double- blind clinical trial. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 10 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 10 of 86 
 1.6 Study Treatments  
All study tr
eatments appear identical.   
Each study medication dose will consist of one over- encapsulated tablet containing either :  
‚Ä¢ CL-108 5 mg (hydrocodone 5 mg/APAP 325 mg/ promethazi ne 12.5 mg); 
‚Ä¢ hydrocodone 5 mg/APAP 325 mg (Norco¬Æ); or 
‚Ä¢ placebo .  
1.7 Samp
le Size  
The study
 is sized to determine the occurrence of vomiting or the use of anti -emetics(opio id-
induced nausea and vomiting, or OINV) of CL -108 5 mg compared to hydrocodone 5 mg/APAP 
325 mg over 48 hours ( Section 7.4.2 below). 
Approximately t hree hundred and thirty  (330 ) patients  will be enrolled so that three hundred 
(300) completed patients can be evaluated  within three treatment groups:  CL-108 5 mg   (n = 
120), hydrocodone 5 mg/APAP 325 mg (n =  120), placebo (n = 60). 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 11 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 11 of 86 
 1.8 STUDY FLOW CHART  
  
       V1 
Screen  V2 
( ‚â§3 
mo)  0 0.5 h r -
12 hr s 13-24 
hrs 24-48 
hrs Day 
3-7 V3    
(¬±2 d)  
Informed Consent  X        
Medical History  X X       
Nausea Prone Questionnaire (NPQ) Health 
Questionnaire  X        
Foot X -ray6 X X       
Physical Examination  X X10       
Urine  Drug Screen  11 X X       
Urine cotinine test  X X      X 
Urine Pregnancy Test7 X X      X 
Vitals Signs  (aural  temp, HR, BP, RR)8 X X X X X X  X 
Height and weight (BMI)  X        
Surgical Procedure   X       
Pain Intensity Categorical Scale (PI -CAT)   X      
Pain Intensity Numerical Rating Scale (PI- NRS)1,2    X X X    
Nausea Scale (NS)1,2   X X X    
Vomiting Frequency Scale (VFS)3   X X X    
Opioid Symptom Scales (OSS)4   X   X   
Administration of  Study Medication9   X X X X X  
Follow -up Telephone Call5       X  
Adverse Events                                  X X  X X 
Use of Rescue and other Concomitant  Medications  X X  X X  X X 
Suture R emoval         X 
Return Diary, M edication Bottle        X 
1 PI-NRS and NS administered half -hourly (scheduled time ) from 30 mins - 12 hrs . 
2 PI-NRS and NS (with  VFS) administered hourly  from 13 - 48 hrs (when  the patient is awake) .  
3 VFS administered  hourly  from 1 -48 hrs (when  the patient is awake).   
4 OSS admini stered at baseline, 24 hrs  and 48 hrs. 
5 The Study Coordinator will telephone the patient approximately 24 hours (+2 days)  after discharge from the study . 
6  The Investigator will exa mine a foot  x-ray before surgery at Visit 2 if not completed  at Visit 1 (e .g., if the x -ray was not obtained in the 
last 6 months  of Visit 1  or is unavailable).  
7 All female  patients  (regardless of childbearing potential ) will undergo urine pregnancy testing at the beginning of Visits 1, 2 and 3.  
8 At screening  (Visit 1) , body temperature ( aural ), heart rate, blood pressure and respiratory rate will be measured while semi -recumb ent for 
at least 5 minutes.  The same measurements  will also be performed (semi -recumb ent for at least 5 minutes ) before surgery, at Baseline,  at 
6 hours, at 12 hours, at 18 hours, at 24 hours, at 48 hours, and at Visit 3  before discharge.  
9 Each  patient should receive 1 dose of study medication at  4-hour  interval s (for a total of 5 doses of study medication) over  the initial 24 
hours of the study and 1 dose of study medication at 4 -hour  interval s (for a total of 5 doses of study medic ation) over the final 24 hours of 
the study while in -clinic (for a total of 10 doses over 48 hours) .  On Days 3 -7 each patient may self -dose with study medication every 4-6 
hours as neede d. 
10 A brief physical exam will be performed at V2 prior to surgery.  
11 A positive urine drug screen will exclude the subject from participating in the study.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 12 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 12  of 86 
 2 Background and Rationale for the Study  
CL-108 is a bi -layered ta blet (containing hydrocodone 7.5 mg/APAP 325  mg in one layer, rapid -
release promethazine 12.5 mg in the other layer ) formu lated  to provide pain relief a nd to prevent or 
reduce  opioid- induced nausea and vomiting ( OINV ).  Because of its direct action on the receptors of 
the nausea- trigger zone (NTZ) in the brain stem which are stimulated by opioids, promethazine is 
well-suited as anti -emetic treatment of OINV. (Promethazine is approved for the prevention and 
treatment of nausea and vomiting as tablets, each containing 12.5 mg, 25 mg, or 50 mg, with 
directions for using 1- 2 tablets every 4 -6 hours.) Two randomized, double -blind, placebo-controlled 
Phase 3 trials (CLCT -002, CLCT -003) have been conducted demonstrating significant effects on 
pain by  CL-108 compared to placebo and on OINV compare d to the active control (hydrocodone 7.5 
mg/APAP 325 mg).    
Other  hydrocodone/ APAP product s (s uch as Norco¬Æ) are approved that contain hydrocodone 5 mg 
with APAP 325 mg per tablet.  
The purpose of the current study is to demonstrat e the efficacy an d safety of a 5-mg version of CL-
108: CL-108 5 mg is a bi- layered tablet containing hydrocodone 5 mg/ APAP 325 mg in one layer, 
rapid -release promethazine 12.5 mg in the other layer. 
The design of the current tri al is consisten t with the study designs  devel oped for previous 
randomized controlled trials on CL-108 .  Included in the current trial, for example , is a Nausea -Prone 
Questionnaire,  or NPQ, an enrichment instrument that was used in both previous Phase 3 trials to 
improve assay sensit ivity by identifying  patients  who are possibly likely to develop OINV  according 
to accepted risk criteria (e.g., a history of previous OINV, nausea/vomiting after a surgical procedure 
or operation, exposure to an opioid, or motion sickness). 1-3, 6-8   
The co-primary OINV objective of the c urrent Phas e 3 trial (CLCT -018) is  to demonstrate the 
preven tion of OINV  by comparing the occurrence of OINV over 48 hours in patients  treated with 
CL-108 5 mg and those treated with hydrocodone 5 mg/APAP 325 mg  (Norco¬Æ).  There are two 
components of the OINV endpoint: the occurrence of any vomiting or use of anti -emetic  medication  
(indicative of nausea)  over 48 hours .  The occurrence and frequency  of vomiting will be  measured 
on a 0-3 Vomiting Frequency Scale , the occur rence of nausea will be measured on a binary Nausea 
Scale, and  the use of anti -emetic medication will be documented in diaries.  
The other co -primary  endpoint of this trial is the relief  of moderate to  severe pain .  Summed pain 
intensity differences over 48 hours (SPID 48) will be compared fo r patients  treated with CL -108 5 mg 
and those treated with placebo .  Pain intensity will b e measured on a 0 -10 Pain Intensity Numerical 
Rating Scale.  
A standard pain model, the  bunionectomy pai n model that was used in CLCT -003, was selected for 
this multiple -dose, randomized, double-blind, placebo- and ac tive-controlled trial.       
The study will be conducted in compliance with the protocol, Good Clinical Practice Guidelines 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 13 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 13 of 86 
 (GCP), and all applicable regulatory requirements. 
3 Objectives of the Study  
‚Ä¢ To com p
are CL -108 5 mg to hydrocodone 5 mg/APAP 325 mg in terms of the occurrence of 
OINV (any vomiting or use of anti-e metic) over 48 hours 
‚Ä¢ To compare CL -108 5 mg to plac ebo in terms of pain reduction over 48 hours (SPID 48) 
4 Trial Design  
This is a
 Phase 3, double- bl ind, randomized, placebo- and active -controlled, multip le-dose study 
conducted at different  research centers in the U .S. comparing  CL-108 5 mg, hydrocodone 5 
mg/APAP 325 mg, and placebo in patients  after first metatarsal bunionectomy (osteotomy with 
fixation of the hea d of the first metatarsal bone) . 
4.1 Visit 1  
Patients  who h
ave called  the research center (spontaneously , by referral  or in response to local 
advertisements  or notification from the center ) to have a bunion on the big toe removed and who 
are potentially qualified according to a pre- screen questionnaire will be scheduled for this 
screening visit.  After patients  sign an Informed Consent  Form  at Visit 1 , a foot x- ray will be 
taken  and reviewed by the surgeon between Visit 1 and Visit 2 prior to surgery  (unless an x-ray 
was obtained within the past 6 months  of Visit 1  another foot x- ray will be obtained ).  The 
patient‚Äôs Medical History will be obtained and  a physical examination will be performed .  Height 
and weight will be measured (to calculate BMI).  After the patien t has been resting in the semi -
recumb ent position for a minimum of 5 minutes, vital signs will be measured  including 
temperature, pulse, respiratory rate, blood pressu re. A urine drug screen and urine cotinine test 
will be performed on all patients . A urine pregnancy test will be perf ormed on each female 
patient  regardless of childbearing potential . Inclusion and exclusion criteria  will be review ed to 
determine  eligibility .  
To identify  the patien t‚Äô s nausea- prone status as suggested on the pre -screen questionnaire , each 
patien t will complete the Nausea- Prone Questionnaire ( NPQ) , documenting previous medical 
and non- medical conditions associated with the development of nausea, including exposure to 
opiates, motion sickness, cigarette smoking, etc. By reviewing responses on the NPQ and using 
specific criteria ( Section 6.3.2 below), the Investigator will determine if the patient could be 
considered  at risk (or not) of opioid- induced nausea and vomiting . Patients  who are not 
considered possibly at risk for OINV or whose  nausea- prone status is uncertain or unknown will 
not be admitted to the trial.  Patients  who meet other admission criteria and whom the 
Investigator considers possibly at risk of OINV will progress to Visit 2.  
Prior to leaving the clinic patients  will be s cheduled for surgery at Visit 2 within 3 months. They 
will take nothing by mouth after midnight on the night  before surgery (including, in particular, 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 14 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 14 of 86 
 no analgesic or anti -emetic medic a tion, although antibiotic prophylaxis for endocarditis  may be 
prescribed , if indicated).   
All patient entries in the Clinic Diary from Visit 1 will be entered onto the electronic  case report 
form
s (eCRFs) by site personnel.   
4.2 Visit 2  
On the day
 of surge ry (Baseline/T reatment Visit)  prior to surgery, the medical  history will be 
review ed, including pre -admission entry criteria, and a brief preoperative physical examination 
will be p erformed with vital signs, which include body temperature ( aural ), respiratory rate, 
pulse, and blood pressure (reclining for 5 minutes) .  A urine drug screen  and urine continue test  
will be performed on all patients  and a urine pregnancy test on all femal e patients .  
Midazolam will be administered according to standard practice pre- operatively  (and intra -
operatively, if necessary).  Regional anesthesia will be established using intravenous propofol 
and a popliteal sciatic nerve block (PSB) using 0.5% ropivacaine.  Patients  will undergo primary, 
unilateral, first metatarsal bunionectomy surgery (osteotomy and internal fixation) with no 
additional collateral procedures.  If the PSB is not sufficient to provide adequate intraoperative 
anesthesia, a standard Mayo block may be established using short -acting lidocaine 1% or 2%  
(plain).  Preoperative antibiotic (e.g., cephalexin) will be administered to all patients ; if there are 
signs of post -operative infection, a patient may receive additional post -op antibiotic (which will 
be documented).  Prophylactic antibiotic for endocarditis, ASA ‚â§ 325 mg for cardiovascular prophylaxis and chronic medications that are not contraindicated ( Section 4.2 below ) are also 
permitted.  Except as permitted by protocol, other me dications (in particular, opioid, anti -emetic) 
are not permitted during or after surgery.  
The PSB will be continuous until approximately 3 am  (¬± 15 minutes )
  of the morning after 
surgery.  Patients  will also receive IM or IV ketorolac 15 or 30 mg (by body weight) at the 
conclusion of surgery, then every 6 hours as needed for breakthrough pain until 1:30 am on the 
morning after surgery (see Section 6.3.3).  
Patients  will be observed in the research center for 9 hours after the popliteal sciatic block is 
discontinued t
o determine if they develop moderate or severe pain as measured on a categorical 
pain intensity rating scale (PI -CAT).   
Moderate or severe b aseline pa in intensity must be confirmed on a 0 -10 numerical rating scale 
(PI-NRS) in order to be eligible for randomization. P atients  who do not report baseline PI -NRS ‚â• 
4 are screen failures.  
Patients  who do not qualify on the PI -CAT and the PI-NRS within 9  hours after discontinuation 
of the PSB will be discharged from the study with routine care.  
All patients  with at le ast moderate pain assessments on the PI -CAT and PI -NRS will complete 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 15 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 15 of 86 
 scales measuring different o p ioid side effect s, including:  
‚Ä¢ a conventional binary Nausea Scal e (NS) to document the presence/absence of nausea;  
‚Ä¢ a Vomitin g Frequenc y Scale (VFS) to document episodes of vomiting, a measurement 
instrument which was used in CLCT-002; 
‚Ä¢ Opioid Symptoms Scales (OSS) , derived from the Symptom Distress Scale to identify 
other opioid effects,4 which were used in CLCT-002 and CLCT-003  
Study medication  will be allocate d to qualifying patients  based on a computer -generated 
randomization code : CL-108 5 mg (n = 120), hydrocodone 5 mg/APAP 325 mg ( HC/APAP,   n = 
120),  or placebo  (n = 60).  Study medication will be administered to patients  under double -blind 
conditions.  
Following the initial dose  of study medication , patients  will remain in the clinic for the entire 48-
hour treatment observation period. The Study Coordinator will impress on the Patients  the 
importance of using a Clinic Dia ry correctly, completing all assessments for the initial 12  hours 
and, when awake,  for the remaining 36  hours of the 48-hour primary treatment observation 
period. 
Vital signs , including tem perature ( aural ), pulse, respiratory rate  and blood pressure (semi -
recumb ent for at least 5 minutes ) will be measur ed at Baseline immediately prior to dosing, th en 
every 6 hours until 24 hours post -dosing. During  the initial 12 hours of the  treatment evaluation 
period, patients  will record assessments every 30 minute s for pain intensity ( on the PI-NRS ) and 
the presence/absence of nausea (on the NS ).  
During the initial 12 hours (beginning at 1 hour) of the treatment evaluation period, at hourly 
inter
vals patients  will use the V FS to assess the occurrence and frequency of vomiting  over the 
past hour. During the remaining 36  hours of the 
 48-hour primary treatment evaluation period  (i.e., at hours 
13-48), when awake, patients  will record  hourly assessments on the PI -NRS, NS  and V FS.  
To provide evaluations of other opioid- related si de effects after multiple doses of study 
medication  taken  over 48 hours , patients  will repeat the OSS at 24 hours  and 48 hours while in 
the research center . 
In order to document  side effects  and any other chan ges in his/her medical condition during the 
48 hours after surgery  (including nighttime) , the Study Coordinator will make hourly 
observations of the patient ‚Äôs status.  All patient reports of a dverse events will be documented on 
the AE page of the eCRF .   
In order to  assure that all patients  assigned to CL -108 5 mg and HC/APAP receive the same total 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 16 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 16 of 86 
 amount of hydrocodone/ APAP  during th e  primary  48-hour treatment observation period, p atients  
will be dosed on a fixed schedule . To comply with label directions for HC/APAP  to not dose 
more frequently than every 4 hours  as treatment for moderate/severe acute pain , the Study 
Coordinator will give the  patient the  second dose of study medication  4 hours after the initial 
dose and the 3rd, 4th and 5th doses also at 4-hour intervals .  As a result, all patients  will receive 5 
doses of study medication over the initial 24 -hour treatment period (i.e., midway between 4 and 
6 total daily doses that are permitted for hydrocodone/APAP).  Dosing every 4 hours for 5 
additional doses during the final 24- hour treatment period will assure that all patients  are 
exposed to the same total amount of analgesic (in particular, hydrocodone)  over 48 hours , 
contributing to the co-primary SPID 48 and OINV  endpoints of the study. Subjects should be 
awoken  for dosing, as needed to remain on the dosing schedule. 
Patients  may take supplementary (rescue) me dication for pain (ibuprofen 400 mg) as needed at 
any time after taking the initial dose of study medication  (every 4 -6 hours, up to 2,400 mg over 
24 hours), but they will be encouraged to wait at least 2 hours  after the initial dose of study 
medication  to allow sufficient time for evalu ation of only the study drug.   
Similarly, patients  will  be encouraged to take a subsequent scheduled dose of study medication 
rather than ibuprofen if the next dose of study medication is due within 1 hour.  However, a 
patient will receive supplementary (rescue) medication for pain any time it is required .  
Anti-emetic rescue medication (prescribed by the Investigator according to standard clinical 
practice)
 is permitted any time after the initial dose of study medication.  
The date(s) and time(s) of taking rescue medications  will b e recorded in the eCRF .   
Patients  will be instructed to provide ratings  on the PI -NRS, NS and V FS prior to each time they 
take rescue medication (s) over the initial 48-hour treatment observation period unless rescue 
medication is taken within 5 minutes after regularly scheduled 30- or 60 -minute assessments .   
Similarly, if a patient who used rescue medication has provided ratings on the PI -NRS, NS an d 
VFS within 5 minutes before regularly scheduled PI -NRS, NS and V FS assessments, these 
regularly -scheduled assessments do not need to be repeated then.   
At all other times r egularly s cheduled PI-NRS, NS, and V FS assessments will not be interrupted 
by the time of using rescue medication.   
If a patient vomits, reports nausea, or takes a dos e of analgesic or an anti -emetic rescue 
medication and then falls asleep, the patient will be awakened for the next scheduled 
assessments.  
Scheduled dosing of s tudy medica tion will also not be interrupted by the use(s) of rescue 
medication  throughout the 48-hour treatment observation peri od. A ll patients  should take all 10 
doses of study medication over 48 hours. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 17 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 17 of 86 
 Patients  who take supplemental medication for pain and/or for nausea/vomiting are expected to 
document a l
l evaluations and side effects throughout the initial 48-hour treatment evaluation 
period in the clinic (and for the remainder of the 7-day study as an outpatient). 
Patients  should continue to use study medication throughout the study in addition to 
supplementa
l medication needed for pain or nausea/vomiting. 
At the c ompletion of the 48-hour PI -NRS,  NS, VFS and OSS assessments, vital signs will be 
repeated  in the semi -recumb ent position, adverse events will be reviewed,  and patients  will 
receive instructions for routine post- op care according to standard clinical pract ice.  
They will be instructed  as out patien ts for Study Days 3 -7 to self-dose with the same assigned 
study medication as needed for pain every 4 -6 hours (for a maximum of 6 doses in a 24-hour 
period), documenting the date and time of each dosing with study medication (and rescue 
analgesic and anti -emetic medications ) in an Outpatient Diary.  All patients will receive a bottle 
of ib uprofen tablets (analgesic rescue medication) and a prescription for an anti -emetic of the 
investigator‚Äôs choice (anti -emetic rescue medication) to be used as needed during Study Days 3 -
7. At the conclusion of Visit 2 patients  will be dis charg
 ed from  the c linic with a responsible adul t. 
All patient efficacy and  safety entr ies in the Clinic Diary from Visit 2 will be entered onto the 
electronic case report forms (eCRFs) by site personnel .   
4.3 Outpatient Phase  (Days 3-7) 
Patie
nts will use an Outpatient Diary each day to doc ument the dose, date and time of each self -
dosing with study medication , each self -dosing with rescue analgesic medication (ibuprofen 400 
mg) and/or prescribed rescue anti -emetic medication , and any other permitted medication (e.g., 
chronic medication) . 
Whether or not they used study medication or rescue medication each day , pa tients  will use the 
Outpatient Diary on Days 3-7 to document any symptoms ( adverse events ) they experienced .  
The Study Coordinator will telephone the patient approximately 24 hours after discharge  from 
the clinic
 after Visit 2  (+2 days, to allow for weekends) to inquire about his/her post -op status, in 
particular, adverse events and uses of pain medication and (rescue) supplemental medications, 
and use of the Outpatient Diary, and to confirm the follow-up appointment. 
4.4 Visit 3 
Approximat
ely 8 days (¬± 2 ) after surgery, patients  will return to the clinic for a final visit,  when 
the patient‚Äôs Outpatient Diary, use s of study medication , supplemental /rescue medications  and 
concomitant medica tions, and all adverse events will be reviewed.  
Vital signs will be measured for all patients  (aural  temper ature, pulse, respiratory rate), and blood 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 18 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 18  of 86 
 pressure ( semi -recumb ent for 5 m inutes), and a third urine pregnancy test will be performed on 
all female patients  and a urine cotinine test will be performed on all patients . All patients  will 
then be discharged from the study. Routine post -op care will be provided according to standard 
clinic al practice, with telephone follow-up for any ongoing side effects until resolution. 
All patient safety entries in the Outpatient Diary will be entered onto the electronic case report 
forms (eCRFs) by site personnel.   
Routine post -operative car e will be provided after discharge from the study. For any continuing 
side effects, the Study Coordinator will call the patient every 48 hours (or routine follow -up) 
until the resolution or stabilization of the side effect.  
5 Patient  Selection and Withdrawal  
5.1 Inclusion  Criteria  
A patient  
will be eligible for inclusion in this study if all of the following criteria apply:  
 
1. Informed consent  Signed informed consent form obtained at screening 
prior to any procedures being performed. 
2. Gender Male or non -pregnant and non-lactating female.  A 
female of child -bearing potential is eligible to participate 
in this study if she has a negative urine pregnancy test 
and is using an acceptable met hod of birth control (i.e., 
hormonal , transdermal, or implanted contraceptives, 
intrauterine device, diaphragm, condom, abstain from 
heterosexual sex , or surgical sterilization). See Section 
5.3. 
3. Age 
4. OINV status  18 years or older  at time of consent . 
Determined by the Investigator as possibl y at risk of 
opioid- induced nausea and vomiting according to 
accepted criteria, as documented  on the Nausea Prone 
Questionnaire. 
5. Foot condition  Primary unilateral first metatarsal bunionectomy 
(osteotomy and internal fixation) with no additional 
collateral procedures.  
6. Pain Severity  Presence of moderate or severe  pain (rating  of 2 or 3)  on 
the 0-3 categorical pain intensity scale (PI -CAT ) at 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 19 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Pag e 19 of 86 
  
7. Pain Confirmation  Baseline . 
Rating ‚â• 4 on the 0 -10 numerical pain intensity scale 
(PI-NRS) at Baseline.  
8. Diary Completion  
9. Safe Transportation Ho me Be willing and able to record safety and efficacy ratings 
in the Diar ies. 
Patient  must have arran gements for transportation home 
from the research center accompanied by a responsible 
adult. 
5.2 Exclusion C riteria  
A patient  w
ill not be eligible for this study if one or more of the following apply: 
 
1. Medical condition  Presence of a serious medical condition (e. g., poorly 
controlled hypertension or diabetes, neurological 
disease including Parkinson‚Äôs or other condition 
associated with a movement disorder, chronic pain, 
significantly impaired cardiac, renal, hepatic, 
respiratory, or thyroid function) , intolerance to NSAIDs 
(e.g., dyspepsia), or any other medical condition which, 
in the opinion of the Investigator, makes the patien t 
unsuitable for participation . 
2. Infection  Acute  infection of the surgical site at the time of sur gery 
that could confound post- surgical evaluation . 
3. Drug Allergy                      History of hypersensitivity (i.e., allergy1) to an opioid 
drug (such as hydrocodone), promethazine, 
acetam inophen, NSAID (such as ibuprofen or aspirin), 
midazolam, propofol, mepivacaine, ropi vacaine or 
ketorolac or history of a dystonic/ dyskinetic reaction  to 
anti-emetic or anti -psychotic medication . 
4. Confounding  and Other than protocol -permitted medications adminis tered 
                                                 
 
1 Because this is a study on opioid -induced nausea and vomiting (OINV), patients with a history of these opioid effects 
will not be excluded from the study. In fact, ‚Äúnausea -prone‚Äù patients (especially those wi th a history of OINV) are sought 
in order to enrich enrollment in  this study. Thus, for example, if patients erroneously consider themselves ‚Äúallergic‚Äù to a 
narcotic, such as codeine, because they felt nauseated or ‚Äúsick to my stomach‚Äù after using a cough medicine, they are 
admissible.  Only medically -defined allergic reactions to an opioid (e.g., rash, hives) should prevent a patient from being 
admitted into this study.  
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 20 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 20 of 86 
 Contraindicated Drugs  pre-operatively  or during surgery: use within 14 days 
before or during the surgical procedure of any systemic 
corticosteroid or use within 24 hour s or during the 
surgica l procedu re of any confounding prescription or 
non-prescription drug (e.g., anal gesic, anti -emetic, 
sedating anti histamine,  sedative, alcohol ,  or CNS/  
psychotropic agent, including sleep aides, 
benzodiazepines, performance/attention enhanc ers, 
marijuana, anti -depressants) or any drug contraindicated 
with hydrocodone, acetaminophen, or promethazine . 
[Note: Antibiotic  for endocarditis prophylaxis (except if 
known to cause nausea) and aspirin (ASA) ‚â§ 325 mg for 
cardiovascular prophylaxis are permitted during the 
study. ]  
 
History of consuming more than 2 alcoholic drinks per day every day for the last month or a positive urine test 
for opiates, benzodiazepines, barbiturates, THC, 
methamphetamines, cocaine, oxycodone , cotinine at 
screening or the morning of surgery will exclude the 
patient from the trial.  
5. Caffeine Use  Ingestion of any caffeine -containing bevera ge or 
choc olate since mid night on the night before surgery. 
6. Nicotine Use  
 Use of any nicotine -containing product (cigarettes, e -
cigarettes, patches, etc.) within the past 30 days.  
7. Investigational Drug Use  Use of an investigational drug within the past 30 days.  
8. Participated in Study  Previous participation in this study.  
9. Pregnancy, Lactation  Women who are pregnant or lactating.  
    10.   Compliance  
    11.   Participant relationship  Inability to swallow capsules whole.  
Employee at the research center, employee of the 
Principal Investigator, Sub- Investigators, Charleston 
Laboratories  or Daiichi Sankyo or relative of the 
Investigator, Sub- Investigators or research staff who is 
involved in this study. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 21 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
&+$5/(6721 /$%25$725,(6 ,1&
3URWRFRO1R&/&7

$XJXVW &21),'(17,$/ 3DJ HRI
8VHLQ)HPDOHV
7KHXVHRIDQ\GUXJLQZRPHQZKRDUHRIFKLOGEHDULQJSRWHQWLDOSUHJQD QWODFWDWLQJUHTXLUHVWKDW
WKHSRWHQWLDOEHQHILWRIWKHGUXJ LVZHLJKHGDJDLQVWWKHSRVVLE OHKD]DUGWRWKHPRWKHUDQGFKLOG
,QYLHZRIWKHVHFRQVLGHUDWLRQV IHPDOHSDWLHQWVDUHRQO\HOLJL EOHWRSDUWLFLSDWHLQWKLVVWXG\LI
WKH\GHPRQVWUDWHDQHJDWLYHXULQHEHWD+&*WHVWUHVXOWDW9LVLW DQGSULRUWRVXUJHU\DW9LVLW
FRQILUPHGDW9LVLW
3UHJQDQF\2FFXUULQJ' XULQJD&OLQLFDO7ULDO
,IDQ\IHPDOHSDWLHQWEHFRPHVSUHJQDQWZKLOHHQUROOHGLQWKLVV WXG\DVFRQILUPHGE\DSRVLWLYH
XULQHEHWD+&*WHVWUHVXOWDW9LVLWVKHVKRXOGQRWLI\WKH, QYHVWLJDWRULPPHGLDWHO\DQGEH
ZLWKGUDZQIURPWKHVWXG\,IDSSOLFDEOHDOOVWXG\VXSSOLHGVX SSOHPHQWDOUHVFXHPHGLFDWLRQV 
PXVWEHUHWXUQHGE\WKHSDWLHQW,IDQ\IHPDOHEHFRPHVSUHJQDQW DVFRQILUPHGE\DSRVLWLYH
XULQHSUHJQDQF\WHVWDWIROORZ XSDQGKDVWDNHQVWXG\PHGLFDWL RQWKH,QYHVWLJDWRUPXVWQRWLI\
,1&¬∂V 3KDUPDFRYLJLODQFH +RWOLQH DW  RU (PDLO DW
ZLWKLQKRXUVRIOHDUQLQJDERXWWKHSUHJQDQF\:LWKLQ
WKHIROORZLQJZHHNVWKH,QYHVWLJDWRUPXVWFRPSOHWHWKH3UHJQ DQF\1RWLILFDWLRQIRUP7KH
,QYHVWLJDWRUZLOOEHUHTXLUHGWRIROORZWKHSDWLHQWXQWLOGHOLY HU\RUWHUPLQDWLRQRIWKHSUHJQDQF\
SURYLGLQJQHFHVVDU\XSGDWHGLQIRUPD WLRQXVLQJWKH3UHJQDQF\1RW LILFDWLRQ)ROORZ8SIRUP
8VHRI6XSSOHPHQWDO5HVFXH0HGLFDWLRQ
7KHUHDUHWZRW\SHVRIVXSSOHPHQWDOUHVFXHPHGLFDWLRQDQDOJH VLFPHGLFDWLRQDQGDQWLHPHWLF
PHGLFDWLRQ  ,I SDWLHQWV H[SHULHQ FH SRVWRSHUDWLYH SDLQ WKDW UH TXLUHV VXSSOHPHQWDO UHVFXH
DQDOJHVLFPHGLFDWLRQWKH\PD\WDNHLEXSURIHQPJZKLFKZLO OEHVXSSOLHGHYHU\KRXUV
XSWRPJRYHUKRXUV
,ISRVVLEOHWRDOORZVXIILFLHQWWLPHIRUHYDOXDWLRQRIWKHVWX G\PHGLFDWLRQDORQHSDWLHQWVZLOOEH
HQFRXUDJHGWRZDLWDWOHDVW KRXUVDIWHUUHFHLYLQJWKHLQLWLDO GRVHRIVWXG\PHGLFDWLRQEHIRUH
WDNLQJ VXSSOHPHQWDO DQDOJHVLF   6LPLODUO\ EHWZHHQ VXEVHTXHQW G RVHV RI VWXG\ PHGLFDWLRQ
SDWLHQWVZLOOEHHQFRXUDJHGWRZDLWXQWLOWKHQH[WVFKHGXOHGGR VHRIVWXG\PHGLFDWLRQ+RZHYHU
SDWLHQWVPD\WDNHVXSSOHPHQWDODQ DOJHVLFPHGLFDWLRQDQ\WLPH,I DSDWLHQW¬∂VSDLQFDQQRWEH
FRQWUROOHGGXULQJWKHVWXG\WKHSDWLHQWZLOOEHGLVFRQWLQXHGI URPWKHVWXG\DQGWUHDWHGDFFRUGLQJ
WRFRQYHQWLRQDOVWDQGDUGRIFDUH
,IDSDWLHQWUHTXLUHVVXSSOHPHQWDOUHVFXHDQDOJHVLFDIWHUWKH WKGRVHRIVWXG\PHGLFDWLRQ
ZKLOHLQWKHFOLQLFDQRWKHUGRV HRILEXSURIHQPJPD\EHWD NHQSURYLGHGWKHWRWDOGDLO\
GRVHRILEXSURIHQGRHVQRW H[FHHGPJRYHUKRXUV
,I DGGLWLRQDO DQDOJHVLD LV UHTXLUHG DW WKH HQG RI WKH LQLWLDO  KRXU WUHDWPHQW SHULRG WKH
,QYHVWLJDWRUPD\SURYLGHDQ,9 GRVHRIDQRQRSLRLGQRQ$3$3F RQWDLQLQJDQDOJHVLFHJ
NHWRURODFRUPJ,9E\ERG\ZHLJKWDFFRUGLQJWRSDFNDJHL QVWUXFWLRQV
,IDSDWLHQWUHTXLUHVDQWLHPHWLFUHVFXHPHGLFDWLRQWKH,QYHVW LJDWRUZLOOSUHVFULEHDQDQWLHPHWLF&KDUOHVWRQ/DERUDWRULHV,QF
3URWRFRO1XPEHU&/&7&OLQLFDO6WXG\5HSRUW)LQDO
1RY
&RQILGHQWLDO 3DJHRIBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBPI
PI
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 22 of 86 
 at his/her own professional discretion according to standard clinical practice  with dosin g 
a
ccording to labelled directions fo r use .   
Every time a patient receives a supplemental (rescue) analgesic or anti -emetic, the medication 
name, date, time, and dose of supplemental medication  will be recorded in the source document 
and in the eCRF .   
During the initial 48-hour treatm ent period patients  will be instructed to record  ratings  on the 
PI-NRS , NS and V FS prior to each time they take  rescue medication (s).   
If a rescue time is within 5 minutes befor e the time for any regularly scheduled PI-NRS , NS and 
VFS assessments, the regu larly scheduled assessments do  not need to be completed in addition 
to the assessments at the time of taking an analgesic or anti -emetic rescue medication .  If a 
rescue time is within 5 minutes after  the time of recording any regularly scheduled PI -NRS , NS 
and V FS assessments, assessments at the time of rescue do  not need to be repea ted 
At all other times during the initial 48-hour treatme nt period regularly scheduled PI -NRS, NS, 
and V FS assessments will not be interrupted by the time of using rescue medication.  
To assure that all patients  in the CL-108 5 mg and th e hydrocodone 5 mg/APAP 325 mg 
treatment groups receive the same amount of analgesic medication ( 10 doses) over 48 hours, the 
schedule for the administration of study me dication  will not be interrupted by  use(s) of any 
rescue/supplementary analgesic or anti -emetic  medication.   
After discharge from the clinic, if patients  require ant i-emetic treatment during Days 3-7 they 
may take the anti -emetic medication which the Investigator has prescribed according to local 
practice in addition to their study medication for pain. Every time a patient takes an anti- emetic 
medication  on Days 3-7 , he/she will be required to record the name, date(s) and time(s) of 
taking each dose in the Outpatient Diary.  
Patients  who use anti -emetic medic ation during Da ys 3 -7 should continue to use study 
medication if needed  for pain .  If supplemental/rescue analgesic is needed on Days 3 -7, the 
patient may take ibuprofen 400 as needed at any time accordi ng to label directions  (every 4 -6 
hours, up to 2,400 mg over 24 hours).  Every t ime a patient takes rescue analges ic medication  
on Days 3-7, he/she will be required to record the name, date(s) and time(s) of taking each dose 
in the Outpatient Diary.  
Patien ts who take supplemental /rescue  medi cation for pain and/or for nausea/vomiting on Days 
3-7 are expected to document  any side effects experienced each day in the Outpatient Diary . 
5.6 Withdrawal  
Patients  may
 withdraw from  the study  or withdraw his or her conse nt at any time  without 
penalty of loss of clinical care or patient rights to which they are entitled .   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 23 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 23 of 86 
 If a patient drops out of the study  during the i nitial 48 hours of the study, he/she  will be ask ed to 
record on the PI -NRS , NS, VFS  and OSS at that time, and the date and time will be recorded on 
a separate CRF  page.  Instructions for using these scales at the time of withdrawal are:  
For the PI -NRS  ‚Äì On a sc ale of 0 to 10, where 0 is ‚Äúno pain‚Äù and 10 is ‚Äúsevere pain,‚Äù 
circle the number that best describes your pain now . 
For the NS  - Over the past half -hour , have you had any nausea (feeling like  you wanted 
to throw up)? 
For the V FS ‚Äì How many t imes did you vomit (throw up) over the past hour ? 
For the OSS  - Circle t he number that best describes each symptom you‚Äôve had since you 
began taking study medication. 
The Investigator should also perform the  following evaluations and procedures  before discharge 
from Visit 2 : 
‚Ä¢ Pregnancy test  (in femal es) 
‚Ä¢ Clinical adverse event assessment  (which wi ll be followed until resolution in 
consultation with the Medical Monitor) 
‚Ä¢ Review of use of concomita nt medication s 
‚Ä¢ Review of use of study medication 
‚Ä¢ Review o
f use of rescue medications  
‚Ä¢ Review of co
mpleteness of diary entries  
5.6.1 Investig
ator‚Äôs Reasons for Patient Withdrawal  
The Investigator may withdraw a patient  from the  study if:  
‚Ä¢ a patient i s unable to unde rstand or use any of the rating scales; 
‚Ä¢ a patient h as an ex clusion criterion after study enrollment (e.g., positive urine 
pregnancy test , cotinine test,  or drug screening test prior to surgery); 
‚Ä¢ continuing to participate in the study would, in the opinion of the Investigator, 
pose a ri
sk to the safety and welfare of the patient.  
The Investigator will also with draw a patient  upon reques t of Charleston Laboratories or 
if Charleston Laboratories  terminates the study.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 24 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 24 of 86 
 Upon occurrence of a serious or  intolerable adverse event, the Investigator or designee 
will confer immediately with the Medical M onitor. Serious adverse events will be 
reported to Charleston Laboratories within 24 hours of determination.  If a patient  is 
discontinued due to an adverse event, the event will be followed until resolved or 
stabilized . 
5.6.2 Handling of Withdrawals  
If a patient  w
ithdraws or is withdrawn from the st udy because of a serious or intolerable 
adverse event  after Visit 2 , the Investigator must make every effort to perform the 
following evaluations and procedures at a follow -up visit: 
‚Ä¢ Pregnancy test  (in femal es) 
‚Ä¢ Clinical adverse event assessment  (which w ill be followed until resolution in 
consultation with the Medical Monitor) 
‚Ä¢ Review of use of concomita nt medication s 
‚Ä¢ Review of use of study medication  
‚Ä¢ Review o
f use of rescue medications  
‚Ä¢ Review of co
mpleteness of diary entries  
These data 
are to be entered into  the case repor t form and comprise an essential safety 
evaluation, which should be completed before  discharg e from the study. 
If a patient  withdraws from the study at any time prior to completion at the patient 's 
request or the Investigator 's discretion, t he reason(s) for withdrawal shall be recorded by 
the Investigator on the appropriate elect ronic case report form (eCRF). If possible at a 
follow- up visit, a ll patients  who wit hdraw from the study after dosing  for non- adverse 
event -related reasons will undergo all procedures and assessments  listed above at that 
time.  
Patients  who withdraw from treatment because of an adverse event or a serious adverse 
event afte
r dosing will be followed until resolution. 
6 Study Procedures  
6.1 Evaluati
ons of Safety and E ligib ility 
Safety evaluations will include the following to determine eligibility to participate in the study and to detect
 any chan ges from baseline:  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 25 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 25 of 86 
 Medical history and physical examination:   At the screening  visit a medical history, including 
medication  history, will be obtained from the patient, and a limited pre-surge ry physical 
examination  will be performed to determine that the patient  qualifies for the study (e.g., without 
medical or concurrent pharmacologic contraindications) . 
Vital Signs:  At screening, body temperature ( aural ), heart rate, blood pressure  and respiratory 
rate will be measured after the patient has been in the s emi-recumb ent position for at least 5 
minutes , and height and weight (to determine BMI) .  The same measurements  will also be 
performed (with the patient s emi-recumb ent for 5 minutes): before  surgery at Visit 2; at 
Baseline; every 6  hours (¬± 10  minutes) following dosing  for 24  hours post initial dose if the 
patient is awake; at 48 hours (¬± 10 minutes) ; and at Visit 3,  before discharge from the study.  
Drug Screen : A urine toxicology scr een test (including opiates, benzodiazepines, barbiturates , 
THC , methamphetamines, cocaine, and oxyco done ) will be performed on each patient  at the 
Screening Visit and on the morning before surge ry.  A positive result will exclude the patient 
from participating in the trial.   
Cotinine Test:  A urine cotinine test will be performed on each patient at the Screening Visit and 
on the morning before surgery. A positive result will exclude the  patient from participating in the 
trial. A urine cotinine test will also be performed at Visit 3.  A positive result will indicate that 
the patient used nicotine during the trial. 
Pregnancy T est: All f emales regardless of childbearing potential must have a urine beta HCG 
pregnancy test performed at screening and on the morning before  surge ry.  A positive result will 
exclude the patient  from parti cipating in the trial.  
A repeat beta HCG urine pregnancy test will be performed at follow-up Visit 3. 
Pain Asse ssment s:  Patients  will be asked to record their level of post -operative pain on  the 0-to-
3 (no pain, mild pain, moderate pain, severe pain) categorical pain intensity scale , or PI -CAT .  
Only patients  with moderate or severe pain rat ings (2 or 3) are eligible for the trial.  
Confirmation of at least moderate pain is required on the 0-to-10 numerical pain intensity scale, 
or PI-NRS (i.e., a Baseline rating  ‚â• 4). 
Clinical adverse event assessment : All adverse events  will be recorded  by the Study Coordinat or 
or designee  in the electronic case report form  (eCRF) according to Section 9.1 of this protocol.   
All adverse events will be followed until resolution  or stabilization . 
6.2 Evaluations of Efficacy and Safety (See Appendices  for Sample Indices ) 
6.2.1 Categorical Pain Intensity S cale (PI -CAT)  
(c
alled ‚ÄúPain ‚Äù in the Clinic  Diary)  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 26 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 26 of 86 
 The p atient  will be as k ed at baseline to ‚ÄúCircle the number that best descr ibes your pain 
now‚Äù on a 0- to-4 Likert scale.  (No Pain/Mild Pain/Moderate Pain/ Severe Pain)  
6.2.2 Numerical Pain Intens ity Rating Scale (PI -NRS)    
(called ‚ÄúPain Severity‚Äù in the Clinic Diary)  
The p atient  will be asked  at baseline and at every post treatment assessment time  to 
‚ÄúCircle the number that best describes your pain now‚Äù on a 0 -to-10 Likert scale.    
The Numerical Pain Intensity Rating Scale  is the m easurement instrument for the co-
primary analgesia endpoint. 
6.2.3 Nausea  Scale (N S)  
(called ‚ÄúNausea‚Äù in the Clinic D iary) 
Nausea w
ill be defined for  each patien t at baseline (‚Äú Nausea is  feeling like  you want to 
throw up‚Äù ).  
At baseline and every 30 minutes after initial treatment until 12 hours, the patient will b e 
asked  ‚ÄúOver the past half -hour, have you had any nausea (feeling like  you wanted to 
throw up)?‚Äù  using a binary scale (no nausea,  nausea).    
The patient will use the Nausea Scale e v ery 6 0 minutes from 13 hours through 48 hours 
(when  the patient is awake)  in response  to the question: ‚ÄúOver the past hour, H ave you 
had any nausea (feeling like  you wanted to throw up)?‚Äù    
The Nausea Scale is the measur ement inst rument for documenting the occurrence (or 
absence) of nausea.  
6.2.4 Vomiting  Frequency Scale (V FS)  
(calle d ‚ÄúVomiting ‚Äù in the Clinic  Diary) 
The p atient  will be instr ucted at baseline and every hour post treatment  over the initial 48 
hours after dosing : ‚ÄúHow often did you vomit (throw up) over the past hour?‚Äù using an 
ordinal scale (not at all, one time, two times, three or more times).  
The V omiting Frequency Scal e is the measurement instrument for documenting the 
occurrence of vomiting in the co- primar y OINV endpoint , as in CLCT -002. 
6.2.5 Opioid Symptom Scales (OSS) (from the Symptom Distress Scale)4  
(called ‚ÄúOther Symptoms‚Äù in the Clinic D iary) 
To docume
nt each of 9 o ther symptoms commonly experienced by patients  using opioids 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 27 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 27 of 86 
 (dizziness, drowsiness, constipation, difficulty voiding, confusion, headache, itch, 
difficult y
 concentrating, dry mouth), at Baseline, at 24 hours, and at 48 hours the patient  
will be instructed  ‚ÄúFor each symptom you‚Äôve had over the past  24 hours , circle the 
number that describes how severe it was for you‚Äù using an 11- point numerical rating 
scale for each symptom.  
The O pioid S ymptom Scales  are m easurement instruments for  documenting the 
occurrence and severity of each other opioid- related symptom, as  in CL CT-002 and 
CLCT -003. 
6.2.6 Uses of Supplemental (R escue) Ana lgesic Medication   
The date, time, name (ibuprofen) , and dose  (400 mg)  o f each use of supplemental (rescue) 
medication  for pain will be recorded in the eCRF. 
6.2.7 Uses of A nti-e meti c (Rescue) Medication  
The date, time , name, and dose  of each use of  anti-emetic medication prescribed by the 
Investigator will be recorded in the e CRF.  
6.2.8 Patient Reports of A dverse Even ts (E licited and Volunteered ) 
Patients  will be asked how they are feeling on an hourly basis throughout the initial in -
clinic 48-hour tre
atment evaluation period  (when they are awake).  The Investigator will 
rate each side effect on a 1 -3 scale (mild, moderate, severe).   All ratings of adverse event s, 
their relationship to study medication, remedial treatments , etc. will  be documented and 
entered on the Adverse Events page of the e CRF.  
Expected post -operative side effects  (i.e., side effects such as localized erythema and 
numbness that the investigator considers related to the surgery ) will not be recorded as 
AEs.  
6.3 Study Conduct  
6.3.1 Pre-Scr
eening Pr ocedures  
Patients  who respond to local advertisements or who are otherwise recruited to the 
research cen
ter (by social media, patient rosters  at the clinic , etc. ) will be pre-screened 
over the tel ephone or in person as potential patients  for the study  using a screening 
questionnaire .  In addition to routine demographic questions, patients  who w ant to have a 
bunion removed will also be asked  questions to determine if they are possibly at risk for 
OINV  (e.g., any allergy to a medication, including pain- killers ; any  reactions such as  
nausea or vomiting after surgery ; any history of motion sickness ; current smoking 
status/ use of nicotine -containing products ) and asked about  their willingness  to comply  
with study requirements (e.g., 3 visits, use of a diary)  if they are accepted into the study .  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 28 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 28 of 86 
 Patients  who appear to qualify for the study will receive appointments for Visit 1  within 
the nex t m
onth. 
6.3.2 Screening Procedures  (Visit 1)  
Patients  18 years of a ge a nd older who request  a bunionectomy  will be evaluated at the 
Screening Visit .  After the in formed consent form has been signed, the following 
procedures will be completed  in order to assure eligibility according to the admission 
criteria : 
‚Ä¢ Urine drug screen on all patients  
‚Ä¢ Urine cotinin
e test on all patients  
‚Ä¢ Urine pregnan
cy test on all female patients  (regardless  of child-bearing  potential)  
‚Ä¢ Physical examination,  height and weigh t (to calculate BMI) , vital signs  (semi -
recumb ent for 5 minutes ) including temperature ( aural ), pulse, respiratory rate, 
systolic and diastolic blood pressure 
‚Ä¢ Evaluation of a foot  x-ray taken within  the past 6 months prior to screening visit . 
If a patient does not have a foot  x-ray taken within the past 6 months, it will be 
obtained and revie wed by the surgeon (to confirm the diagnosis of a first 
metatarsal bunion) at  Visit 1 and /or prior to surgery at Visit 2   
‚Ä¢ Medical History  including admis sion criteria , gender, smoking status/use of 
nicotine-containing products, and me dications taken in the past 30 days 
‚Ä¢ Nausea -Prone Questionnaire (NPQ) (See Appendix 3) 
As part of 
medical -history taking, p atients  will be asked to complete a ‚ÄúHealth 
Questionnaire‚Äù which contains more than the Medical History and is designed to identify 
patients  who are  possibly at risk of opioid- induced nausea and vomiting (OINV).  
Patients  will be asked a series of questions about different conditions  associated with 
nausea (e.g., previous OINV , nausea after a post -op medication, nausea/vomiting after 
Vicodin, ‚Äúallergy‚Äù to cough medicines , previous exposure to an opioid medication, sea 
sickness , other types of  motion sickness)  based on  risk factors identified by Apfel et al1-3 
and Gan et al .6-8  
Responses on the NPQ will be used by the Investigator to qua lify a patient as being 
possibly at risk for  OINV according to  pre-determined criteria (A-D): 
Criterion A :  Any one of the  following 5 responses to Questions 4- 5, 7, 8 on the 
NPQ will be interpreted as meaning the patient is possibly at risk of OINV:  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 29 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 29 of 86 
 ÔÇß Reports being ‚Äúallergic‚Äù to an opioid- containing  drug and  the symptoms 
reported are determined to be nausea or vomiting (Q 4-5) 
ÔÇß Has taken an opioid- containing drug and became  nauseated or vomited (Q  4-
5) 
ÔÇß Has taken an unknown medication after an operation or surgical procedure 
and became na
useated or vomited (Q7-8) 
ÔÇß Reports being ‚Äúallergic‚Äù to cough medicine and the symptoms reported are determine
d to be nausea or vomiting (Q4 -5) 
ÔÇß Has taken a cough medicine (naming the opioid in it or  not) and bec ame 
nauseated  or vomited  (Q4-5) 
Criterion B :  If a pa tient has at least one of the following 5 responses to Questions 
26-27, 30, 32-34, (relating to  motion sickness) on the NPQ, the patient will be 
considered possibly at risk of OINV:  
‚Ä¢ Easily becomes nauseated when riding in a car (or requires an open window 
when riding in a car) (Q26 -27) 
‚Ä¢ Easily becomes nauseated when riding backwards in a train (Q30) 
‚Ä¢ Easily becomes nauseated when on a roller- coaster  (Q32) 
‚Ä¢ Easily becomes nauseated when spun around (Q33)Easily becomes  
nauseated when bending over (Q34)  
Criterion C :  Any rati ng ‚â• 3 on Question 43 of the NPQ ( which is a 0-10 Nausea -
Prone Scale) will also be interpreted as meaning the patient is possibly  at risk of  
OINV.  
Criterion D :  If Criter ia A -C does not qualify a patient, the Investigator may 
consider a patient possibly at risk of OINV  based on other responses on the NPQ 
(which the Investigator will identify, such as Questions 16- 18, 21, 25, 28, 31, 39, 
gender, smoking status). The Investigator may thus use ‚Äúclinical judgment‚Äù to admit 
up to approximately  10% of the total number of qualifying p atients  at his/her research  
center.  
In sum, as a result of using the NPQ the Investigator will admit patients  with a histor y 
suggestive of a predisposition for developing OINV , thus providing an enriched group of 
patients  for evaluation at Visit 2 . 
The Investigator will cite each question on the NPQ that led to his/her determination that 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 30 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 30  of 86 
 the patient is possibly at risk for OINV.   
Admission criteria will be reviewed to assure eligibility to the study.   Patients  who 
quali f
y will be scheduled for surgery within 90 days.   
Patients  who do not qualify will have their reason(s) for ‚Äúscreen failure‚Äù documented in 
the eCRF and wi
ll not progress in the study. 
6.3.3 Surgery Day (Visit 2 ) 
With in 90 days after Visit 1, s creened p atients  who qualify for  the study will report in the 
morning to the center having fasted since midnight.  
(Exception:  If a subject has consumed a small sip of liq uid or small amount of food  since 
midnight , the Investiga tor will determine if it is safe for the subject to have surgery under 
local anesthesia.)  
Prior to  surgery, the follow ing will be performed: 
‚Ä¢ Documentation of concomitant medications (see Section 5.2, Exclusion #4) 
‚Ä¢ Urine d
rug s creen  
‚Ä¢ Urine c
otinine test  
‚Ä¢ Urine preg
nancy test for all female patients  
‚Ä¢
 Review of the Medical History  
‚Ä¢ Vital signs (
semi-recumb ent for 5 minutes), including temperature ( aural ), heart 
rate, respiratory rate and blood pressure (systolic and diastolic) 
‚Ä¢ Surgeon‚Äôs assessment of the foot x-ray (at Vi sit 1, between Visits 1 and 2, or  prior 
to surgery at Visit 2)   
Moderate regional anesthesia will be standardized for all patients: patients  will r eceive 
midazolam and/or propofol for initial sedation at the anesthesiologist‚Äôs discretion.  Afte r 
adequate sedation is achieved, the anesthesiologist will inject approximately 5 mL 
lidocaine 1% or 2% (plain) locally to anesthetize the skin and will determine the location 
of the sciatic nerve for the popliteal sciatic block (PSB) using a nerve stimula tor per 
standard technique.  Once the appropriate location is determined and the catheter secured, 
the anesthesiologist will inject approximately 40 mL of ropivacaine 0.5% to establish the 
PSB via the catheter.  Subsequently, the catheter will remain in place in the proximity of 
the popliteal sciatic nerve for delivery of postoperative anesthesia.   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 31 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 31 of 86 
 Patients  will undergo primary, unilateral, first metatarsal bunionectomy surgery 
(osteotomy  
and internal fixation) with no additional collateral procedures.  If the PSB is 
not sufficient to provide adequate intraoperative anesthesia, a standard Mayo block may 
be established using short -acting lidocaine 1% or 2% (plain, without epinephri ne), not to 
exceed 25 ml..   
Pre-operative antibiotic (e.g., cephalexin) will be administered to all patients ; if ther e are 
signs of post -operative infection, a patient may receive additional post -op antibiotic 
(which will be documented).  
Prophylactic antibiotic for endocarditis, ASA ‚â§ 325 mg for cardiovascular prophylaxis 
and chronic me
dications that are not contraindicated (see 4.2) are also permitted.  Except 
as permitted by protocol, other medications (in particular, opioid and anti-emetic) and 
any nico tine-containing product are not permitted during or after surgery.  
Patients  will receive IM or IV ketorolac 15 or 30 mg (by body weight, per label) at the 
conclusion of s
urgery.  
Patients  who had bunionectomy surgery performed at the research center and patients  
were trans
ferred to the research center after surgery will stay at the research center for 
study observations and routine post- surgical care.  
The popliteal sciatic block will be maintained until a pproximatel y 3 am  (¬± 15 minutes)  of 
the morning after surgery.  
Postoperative pain will be controlled by a continuous anesthetic infusion through the 
catheter prev
iously placed adjacent to the popliteal sciatic nerve.  Two methods of 
continuous anesthetic infusion are permitted. Mepivacaine 0.5% (plain) will be infused 
starting at 8 mL per hour and not to exceed 14 mL per hour.   
During this  continuous infus ion period, patients  may receive supplemental analgesia for 
breakthrough pain in the following fashion:  
‚Ä¢ First, bolus of mepivacaine (10 mL boluses  injected via the catheter with no more 
than three 10 mL boluses allowed per hour) and/or increase rate of continuous 
local anesthetic infusion by 2 mL/hr (up to a maximum rate of 14 mL/hr).  All use 
of mepivacaine will be discontinued at approx imately 3 am  on the morning 
following surgery. 
Then, ketorolac ( patients  less  than 65 years of age and greater than 50 kg:  30 mg IM or 
IV every 6 hours as needed with maximum daily dose 120 mg; patients  greater than or 
equal to 65 years of age or less than 50 kg: 15 mg IM or IV every 6 hours as needed with 
maximum daily dose 60 mg).  All use of ketorolac  will be discontinued at 1:30 am  on the 
morning following surgery.    
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 32 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 32 of 86 
 Alternatively, postoperative pain will be controlled by a continuous ropivacaine 0.2% 
infusion via P S
B catheter on a PCA pump at a continuous rate of 1 ml/hr.  .  Up to two, 3 
ml boluses of Ropivacaine 0.2% may be given per hr.  If pain is not adequately controlled 
after two boluses, infusion may be increased by 2ml/hr.  All use of ro pivacaine will be 
discontinued at approximately 3 am on the morning following surgery.   
 
During this continuous infusion period, patients may re ceive supplemental analgesia for 
breakthrough pain (patients less than 65 years of age and greater than 50 kg:  ketorolac 30 
mg IM or IV every 6 hours as needed with a maximum daily dose of 120 mg; patients 
greater than or equal to 65 years of age or less than 50 kg: ketorolac 15 mg IM or IV 
every 6 hours as needed with a maximum daily dose of 60 mg ).  All use of ketorolac will 
be discontinued at 1:30 am on the morning following surgery.   
If the regional anesthetic infusion and allowed supplemental analgesia do not effectively 
control the 
patient‚Äôs postoperative pain, then the patient will be discontinued from the 
study.  
During this period, the patient will be instructed how to use the rating scales in the In -
Clinic Diary
.  
The patient  will remain in the study center for routine post- surgical care (but no topical 
or syst emic analgesic treatment ) and for observation for up to 9 hours to observe if the 
patient develops moderate- to-severe pain  after the PSP is  discontinued. During this 
period, the patient  will be instr ucted how to use the rating scales in the D iary. 
6.3.4 Post-Surgical Eligibility Assessments  and Dosing 
During the post -surgical period until 10 minutes pre -dosing, patients  may consume non-
caffeinated liquids and food (no chocolate).  No other treatment is  permitted.    
When the patient has pain at the surgical site, s/he will be asked to rate his/her pain on a 
categorical
 pain intensity scale (PI -CAT). The patient is required to have moderate or 
severe pain to be eligible for the clinical trial as indicat ed by a score ‚â• 2 on the PI -CAT.   
The Study Coordinator will ask patients  with mo derate or severe pain o n the PI -CAT to 
rate their pain using the PI-NRS pain intensity scale (PI -NRS).  The PI -NRS  must 
indicate  at least moderate pain (rating  ‚â• 4) for the patient  to be randomized .  This 
qualifying PI -NRS rating  constitute s the Baseline pain score, which will be recorded in 
the eCRF .   
If 9 hours have transpired since the popliteal sciatic block was discontinued  and the 
patien
t does not indicate moderate or severe pain  on the PI-CAT  and PI -NRS , the patient  
does not qualify for the study and will be c onsidered a screen failure.    These patients  
will be discharged from the study and routine post- operat ive care will be provided.   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 33 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 33 of 86 
 For patients  who qualify  on the PI- CAT  and PI- NRS the Study Coordinator will: 
1. Record  pulse, respiratory rate, blood pressure ( semi -recumb ent for 5  minutes), 
temperature (aural ). 
2. After defining nausea (‚Äú Nausea is  feeling like you want to throw up‚Äù ), administer: 
a) Nausea Scale (NS)  
b) Vomiting Frequency Scale (V FS)  
c) Opioid Symptoms Scales (OSS)  
3. Select the next -numbered randomization study medication.  
4. Assure that the patient has not had any food or drink for 10 minutes prior to 
receiving study medication.  
5. Administer assigned study medication (1 capsule) to the patient with 4 -8 oz. of 
water.   This is the Baseline time.  
6. Examine the patient‚Äôs mouth to assure that the capsule was swallowed. 
7. Set the timer for 30 minutes.  
8. Record the study treatment number and the date and time of administration in the source and electronic CRF.  
For subsequent dosing  of study me
 dication, the Study coordinator will administer one 
dose (1 capsule) of study medication every 4 hours over the initial 12 hours of the 
treatment period  for a total of 4 doses of study medication.  The 5th dose of study 
medication will be administered 4 hours after the 4th dose.  Thus e ach patient  will 
receive the same total amount of study medication, a total of 5 doses over the initial 24 
hours (i.e., mid- way between the total per -label  amounts of 4-6 doses of hydrocodone/  
APAP over 24 hours) .  Subjects should be awoken  for dosing, as needed to remain on 
the dosing schedule. 
 
The Study Coordinator will follow the same schedule of dosing (every 4 hours (¬± 10 
minutes)
 for 5 doses) over the final 24 hours of the treatment observation period in the  
clinic so that all patients  receive the same total amount of study medication (10 doses) 
over 48 hours. 
The study treatment number and the date and time of administration of each dose of 
study m
edication are to be entered into the e CRF.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 34 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 34 of 86 
 When dosing with s tudy medic a tion and assessments of PI-NRS, NS, and V FS are due at 
the same time, the assessments should be done first, followed by dosing. 
Patients are to b e in a semi -recum bent position at least 15 minutes prior to each 
scheduled assessment  time . 
All dose s are to be administered with 4 -8 oz. of  water , and the study staff should 
examine patient‚Äôs mouth to ensure capsule is swallowed.   Patients  should not have food or drink 10 mi
 nutes prior to receiving study medication or 
prior to completing assessments .  Throughout the 48-hour treatment observation period, 
patients  may consume non- caffeinated liquids and food (no chocolate) during the 20 -
minute period following any set of assessments (i.e., patients  may not receive food or 
liquids 10 minutes before any scheduled assessment). Use of any nicotine -containing 
product is also not permitted throughout the 48 -hour treatment observation period (or at 
any time during the 7-day study) . 
No topical  treatment s fo r pain  and no other medications will be administered except 
supplemental (rescue) analgesic and anti- emetic prescribed by the Investigator, if needed.   
6.3.5 Study Times  Initi al 12 Hours Post- Initial Dose   
(every 30 minutes over the initial 12 hours:  at 30 minutes, 1 hour, 1.5 hours , 2.0, 2.5, 
3.0, 3.5, 4.0, 4.5, 5.0, 5.5 hours , etc.  until 12 hours after the initial administration of 
study medication ) 
Every 30 minutes (¬±5 Minutes) the Study Coordinator will: 
1. Instruct the patient to rate  pain intensity (PI- NRS ). 
2. Then instruct the patient to complete the NS . 
3. Set the 
timer  for 30 minutes . 
Every 60 minutes (¬±5 Minutes) the Study Coordinator will: 
1. Instruct the patient to complete the V FS.  
2. Set the timer for 30 minutes. 
Throughout this period th e Study C oordinator will: 
1. Record each use of study medication every 4 hours  so that a total of 4  doses of 
assigned study medication are administered over the  initial 12 -hour treatment 
period. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 35 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 35 of 86 
 2. Record use (s) of suppl e mental /rescue analgesic and anti -emetic medication (s). 
3. Observe for and r ecord  all obs erved or volunteered adverse events  as rated by the 
Investigator (mild, moderate, severe). 
6.3.6 Study Times: 12 Hou rs Post -Initial Dose through 48 Hours  
(every 60 minutes  (if awake) over next 36 hours: at 13 hour s, 14 hours, 15 hours, etc. 
until 48 hours after the initial administration of  study medication )  
Every 60 minutes (¬±5 Minutes) the Study Coordinator will: 
1. Instruct the patient to rate  pain intensity (PI- NRS ) if the patient is awake.  
2. Instruct the patient to rate  NS if the patient is awake .  
3. Instruct the patient to rate V FS if the patient is awake.  
4. Set the timer for 60 minutes . 
5. Observe 
and record patient status (e.g. adverse events) hourly. 
6. Record use
s of study medication:  
a) 1 dose administered 4 hours  after the 4th dose so that  a total of 5 doses of 
study medication are administered over the initial 24-hour treatment period ; 
b) 1 dose administered every 4 hours  for 5 additional doses  during the remaining 
24 hours at the research center , so that a total of 10 doses of study medication 
are administered over the  entire 48 -hour treatment observation period.   
Subjects should be awoken  for dosing, as needed to remain on the dosing 
schedule.  
7. Record use (s) of supple mental /rescue medication (s) if needed . 
8. Record  all obser ved or volunteered adverse events  as rated by the Investigator 
(mild, moderate, severe). 
6.3.7 Study Time: Add itional Assessments at  24 hours (¬±15 Minutes)  
1. Record OSS (after V FS is obtained) . 
2. Set timer for 60 minutes.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 36 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 36 of 86 
 6.3.8 Study Time: 48 ho ur s (¬±15 Minutes) 
1. Record pain intensity (PI- NRS ). 
2. Record
 NS. 
3. Record VFS 
4.
 Record O
SS. 
5. Record t
emperature ( aural ), pulse, respiratory rate, blood pressure  (after semi -
recumb ent for 5 minutes). 
6. Record use (s) of supple mental /rescue medication(s) . 
7. Evaluate adverse events (ongoing adverse events will be monitored until 
resolution)
. 
8. Provide discharge instructions for Study Days 3 -7: 
‚Ä¢ How t o use
 the Outpa tient Diary  every day  
‚Ä¢ Directions for taking/recording each use of st udy medication (every 4 -6 hours 
as needed for pain, up to 6 doses per 24-hour period) 
‚Ä¢ Directions for recording use of supplemental analgesic and/or anti - emetic  
medica
tions  
‚Ä¢ Directions for recording symptoms/ad verse experiences  
‚Ä¢ Explain study conditions for Days 3-7. 
The patie
nt will be reminded that s/he is in a clinical trial and must remain awake until 
his/her us
ual bedtime, staying alert in order to record all uses of study medication and 
rescue medications, if needed, and to document all adverse events  on Days 3  - 7. 
The patient will be instructed that no caffeine -containing beverage, alcohol , chocol ate or 
nicotine- contai ning product may be used during the 7-day study period.  
The patient will also be reminded that no other treatments for pain (including to pical 
treatmen
ts) and no other medications (except the supplemental analgesic prescribed by 
the Investigator, ibuprofen 400 mg) may be taken if needed for pain. 
The patient will be given a prescription for the anti -emetic of t he Investigator‚Äôs choice 
according to local medical practice, with instructions to how to use this medication for 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 37 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 37 of 86 
 nausea/vomit ing, if  needed.  
The patient will also be instructed how to document the names and use of these 
supplemental analgesic and anti -emetic medications, per Section 5.5, above, including 
the requirement to complete all entries in the Outpatient Diary  for 7 days. 
The patient will be advised which ongoing medications (e.g. antihypertensive 
medications) are permitted during the study period and which medications (per exclusion 
criterion #4) are not permitted.  
The patient will also be informe d that the S tudy Coordina tor will contact the patient by 
phone approximately 24 hours after discharge from Visit 2 (or up to 2 days later, to 
account for weekends) to ask how the patient is feeling, adverse events, and any medications taken, to see how s/he is doing post -op and monitor his/her use of the 
outpatient diary. 
The patient will be discharged from Visit 2 with a bottle containing the remaining study 
medication 
capsules, a bottle containing ibuprofen 200 mg tablets ( to be used if needed), 
and a prescription for an anti- emetic( to be used if needed).  
The patient will be released from the research facility only when his/her pre - arranged  
(a
dult) transportation and escort have arrived. 
Patient status and findings will be recorded in the source and e CRF.  
6.3.9 Outpatien
t Activities:  Day 3 through Day 7 
1. Record the date and times of taking study medication at each time dosed. 
2. Record the date and times of taking supplemental analgesic and anti -emetic 
medication(s) at the time(s) used e very day. 
3. Record all symptoms (adverse events) experi enced over the past 24 hours  (even if 
the patient did not take any study medication on a particular day). 
6.3.10 Follow- Up Telephon e Call:  approximately 24 hours after discharge ( +2 days , 
to account for weekends) 
The Study Coordinator will telephone  the patient appr oximately 24 hours after discharge 
(or up to 2 days after discharge if over a weekend) to inquire about the patient‚Äôs post -op 
status ( e.g., pain, bleeding, fever, nausea, vomiting, side effects)  and uses of medications. 
Adverse events and concomitant m edications will be recorded in the eCRF.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 38 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Pag e 38 of 86 
 6.3.11 Follow-Up Visit 3 on Day 8 (¬± 2 days) 
The followi ng
 procedures will be completed at the follow-up visit: 
1. Vital signs ( aural  temperature, pulse, respiratory rate) and blood pressure ( semi -
recumb ent for 5 minutes) will be measured.  
2. Retrieve Outpatient Diary, study medication bottle, supplemental pain and anti -
emetic medication  bottles . 
3. Count remaining study medication capsules, account for the number of study 
medication capsules used and  compliance.  
4. Evaluate adverse events (ongoing adverse events will be monitored until resolved, per Section 9.1, below). 
5. Review use of supplemental /rescue medication(s).  
6. Review and document all concomitant medications.  
7. Perform urine pregnancy test on all female  patients . 
8. Perform urine cotinine test on all patients  
9. Discharge patient from  study with instructions for routine post- op care.  
10. For any continuing side effects, the Study Coordinator will call the patient every 
48 hours (or routine follow-up) until the resolution of the side effect.  
6.4 Concomita nt Therapy 
A
ny concomitant medication used (e.g., antih ypertensive, contraceptive) must be entered in to 
the eCRF .   
6.5 Assignment of N umbers  
Each p
atient  who has signed an informed consent form in the study will be assigned in sequence 
the lowest available ( 3-digit) s creening  number.  
Patients  assigned a s creening  number  but who do not meet inclusion/ exclusion criteria (e.g., do 
not have at least moderate  pain on the PI -CAT  and PI -NRS ) will have the reasons for screen 
failur e entered into the eCRF.  
Patients  who meet inclusion/exclusion criteria and qualify to receive study medication will be 
assigned t
he next available 4 -digit randomization number in ascending sequential order at the 
investigative site.  Each randomization n umber assigns  treatment  according to an independent 
computer- generated randomization schedule.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 39 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 39 of 86 
 6.6 Treatment  
Patients  wil
l be random ized to receive over-encapsulated CL -108 5 mg, hydrocodone 5 mg/ 
APAP 325 mg, or  placebo.  The randomization number for a bottle  of study drug will 
correspond to the double-blind assignment of study drug assigned for an individual patient .  
6.7 Clinical Adverse Events  
A
ll adverse events reported until Visit 3  must be recorded in the case report form according to 
Section 9.1 of this protocol.   All Adverse Events will  be followed until resolution or clinical 
stability . 
6.8 Risks/Precautions  
Hydrocodone 
combined with acetaminophen is a Schedule II  controlled s ubstance that can 
produce drug dependence of the opioid type.  Like other opioids, re spiratory depression has been 
associated with hydrocodone.  Deaths have also been reported in association with concomitant 
administration  of hydrocodone with other depressants such as alcohol or other opioids.  Patients  
should be warned of the potential da nger of the self -administration of benzodiazepines or other 
depressants while under treatment with hydrocodo ne. 
Opioid anal gesics impa ir the mental and/or physical ability required for the performance of 
potentially dan gerous tasks (e. g., driving a car or operating machinery).  Patients  should be 
warned of these dangers and  counseled accordingly.  Patients  in the study will not be released 
from the facility unless their prearran ged transportation has arrived.  
Promethazine is a phenothiazine.  Like other phenothiazines, respiratory depression, seizures, and sedation
 have been associated with promethazine.  Dyskinetic reactions may occur in 
patients  with previous dyskinetic reactions to acute or chronic anti -emetic or antipsychotic 
medicatio ns. Because phenothiazines  impair the mental and/or physical ability required for the 
performance of potentially dan gerous tasks (e. g. driving a car or operating machinery), patients  
should be warned of these dan gers and  counseled accordingly.   
Short- term use of acetaminophen at therapeutic doses is rarely associated with side effects, 
although na
usea and vomiting have been reported with its use.  Patients  who are alcoholics are 
susceptible to hepatotoxicity, even liver failure, if they consume more than 4 grams  of 
acetaminophen per day.  
6.9 Overdos age 
The mani
festations of  overdosa ge with h ydrocodone and promethazine are similar, with the 
most serious effect s being respiratory depression and hypoventilation.  
Immediate mana gement of opioi d overdose includes ensuring a patent airway, physical and 
verbal stimulation of the patient , and assessment of level of consciousness, ventilatory and 
circulatory status.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 40 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 40 of 86 
 In the case of overdose, the primary mana gement should be  the re -establishment of adequate 
ventilation with mechanical assistance of respiration, if required.  Naloxone may be 
administered, if necessary, to reverse opioid -induced  respiratory depr ession .  In the presence of 
hypo -ventilation or apnea, ventilation should be assisted or controlled and oxy gen admi nistered 
as indicated.  
Acetaminophen overdosage can result in hepatotoxicity and acute liver failure.  Treatment is 
aimed at re
moving the acetaminophen  from the body and replacing glutathione. Activated 
charcoal  can be 
used to decrease absorption of acetaminophen  if the pa tient presents for 
treatment soon after the overdose. T he specific antidote for acetaminophen overdosage , 
acetylcysteine,  (also called N -acetylc ysteine or NAC) acts as a precursor for glutathione, helping 
the body regenerate enough to prevent permanent damage to the liver  which, if extensive , may 
requir e liver transplant ation . 
7 Data Collection and Analysis  
7.1 Recordin
g of Data 
Data will
 be recorded from clinical so urce records and patient  diaries into  electronic case report 
forms (eCRFs) by site personnel .  
All missing data must be accounted for. If a space is blank because the item was not completed , 
if the ite
m is unknown, or if the item is not applicable to an individual case the computer will 
flag the blank and the site p ersonnel must add an explanation why the space is blank.  If an entry 
error has been made, the original entry must be corrected.  The computer will record the date of 
the chan ge and the identity of the person making the change. 
All patients  signing  an informed consent form who fail screening or who withdraw before 
randomization must have  the reason(s) entered in the eCRF.  All patients  who are randomized 
will have all data entered in the eCRF . 
7.2 Control M ethods  
Patie
nts will be randomly assigned to receive one of three treatments: CL-108 5 mg, 
hydro
codone 5 mg/APAP 325 mg , or placebo . In case of an emer gency the Investigator  should 
treat the patient assuming  he/she received hydrocodone/acetaminophen/ promethazine.  In an  
unusual event where the safety  of a patient is at risk and unblinding is necessary to treat the 
patient , the bottom (scratch -off) portion of the tear -off label may be access ed.  Diligent attempts 
should be made to contact the Medical Monitor and sponsor prior to unblinding.  The reason for 
unblinding, the time of sponsor contact, and unblinding procedures followed should be carefully 
documented.   
7.3 Safety Assessments  
Ver
batim adverse event  terms will  be coded into standardized system organ classes and 
preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA).  Because 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 41 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 41 of 86 
 sleep disturbance and opioid- relat ed adverse event s contributing to it are of special interest, 
sleep disturbance, nausea, retching, vomiting, and headache  will be summarized and analyzed 
for CL-108 5 mg , hydrocodone 5 mg/APAP 325 mg, and placebo.  
Adverse events will be summarized for CL -108 5 mg, hydrocodone  5 mg/ APAP 325 mg , and 
placebo.  
Concomita nt medicatio ns will be  coded using the World Health Organization Drug Dictionary  
(WHO -DD). 
7.4 Statistical Analysis  
7.4.1 Pr
imary Hypothes es 
This s
tudy will test two co -primary nul l hypotheses: 
‚Ä¢ That CL -108 5 mg has t he same occurrence of vomiting and use of anti -emetic (s) 
as hydrocodone 5 mg/APAP 325 mg 
‚Ä¢ That CL -108 5 mg has t he same analgesic effect as placebo  
This study uses two co- primary e ndpoints, one for the assessment of opioid-induced 
nausea and vomiting (OINV) and one for the assessment of pain. Both endpoints  are 
defined over the initial 48 hours following randomization 
Co-Primary OINV  Endpoint: 
The 
co-primary OINV  endpoint is a binary  assessment of response/no response to a 
composite index consisting  of any vomiting or use of anti -emetic medication (indicative 
of nausea) over 48 hours , comparing CL -108 5 mg to hydrocodone 5 mg/  APAP 325 mg   
Co-Primary Analgesia Endpoint: 
The co -primar
y analgesia endpoint is the time -weighted sum of  pain intensity differences 
over 48 hours (SPID 48), comparing CL-108 5 mg to placebo  
The SPID 48 endpoint is calculated from the PI -NRS values at baseline,  every 3 0 minutes 
until hour 12, then every hour (when awake) until hour    48 as follows: 
‚Ä¢ Each subsequent PI- NRS valu e is subtracted from the baseline PI -NRS  value.  
‚Ä¢ Each difference is weighted by the elapsed time from the previous  PI-NRS value  
to the current one 
‚Ä¢ The weighed differences are summed to yield the SPID 48 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 42 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 42 of 86 
 7.4.2 Sample Size Justification  
A sample s
ize of 300 completed pa tients  is planned  for analysis : 120 p atients  in the CL -
108 5 mg treatment group, 120 patients  in the hydrocodone 5 mg/APAP 325 mg  
treatment group, 60 patients  in the placebo treatment group. 
The rates of observed OINV (any vomiting or use of anti -emetic)  were 11.9% and 45.2% 
for CL -108 7.5 mg and hydrocodone 7.5 mg/APAP 325 mg , respectively,  in a previous 
48-hour bunionectomy study (CLCT -003).  Based on a reduc ed per dose  exposure to 
hydrocodone in the present study (CLCT -018) , the expected incidence of OINV in the 
control group (Norco 5 mg) is estimated to be approximately 30 % (vs 45 % for Norco 7.5  
mg in CLCT -003).  With an absolute delta of .20, the e stima ted incidence of OINV in the 
CL-108 5 mg treatment group is 10%.  With a power of 96.4% and a 2 -sided  2-sample 
chi-square test with an  alpha of 0.05, approximately 110 patients  would be required i n 
each active treatment group.  
The observed means of SPID 48 in CLCT -003 were 118.4 and 53.1 for CL -108 7.5 mg 
and placebo, respectively, and the pooled standard deviation was 75. Based on a 
reduction of hydrocodone exposure (from 7.5 to 5 mg per dose), the  estima ted SPID 48 is 
one-third lower for CL -108 5 mg.  For SPID 48, a sample size of 1 10 patients  in the CL -
108 5mg treatment group and 55 in the placebo group provides  93.7% power using a 2-
sided 2- sample t- test with an alpha of 0.05 for a delta of 43.5 (96.6 vs 53.2) and  SD of 
75. 
The overall power is 90% for the analyses of these 2 co-primary endpoints. Based on the 
number of patients  who do not qualify (eg, because of admission criteria such as low 
baseline pain) or patients  who enroll but do not complete the study, the plan is to enroll 
approximately 330 patients  in order to be able to analyze  a total sample size of 300 
patients  who complete the study.  
7.4.3 Key Secondary Endpoints 
1. Percentag
e of patients with complete absence of OINV ( no nausea, no vomiting, 
and no use of anti -emetic medication)  over 48 hours, comparing CL -108 5 mg to 
hydrocodone 5 mg/APAP 325 mg 
2. Percentage of patients  with any  vomiting  over 48 hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
3. Percentage of patients with any nausea  over 48 hours, comparing CL -108 5 mg to 
hydrocodone 5 mg/APAP 325 mg 
4. Percentage of patients with any nausea or vomiting ove r 48 hours, comparing 
CL-108 5 mg to hydrocodone 5 mg/APAP 325 mg    
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 43 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 43 of 86 
 5. Percentage of patients with Post -Discharg e Nausea and Vomiting (PDNV) over 
days 3 -7 
 
6. Number of doses of study medication taken over days 3-7 
 7. Number of dos
es of study medication taken per day over days 3-7 
 
 
7.4.4 Labeling E
ndpoints 
Specific
 endpoints will be presented in sequence to support a label stating that: 
1.  CL -108 5 mg relieves moderate to severe pain  
2.  CL -108 5 mg preve
nts opioid-induced nausea and vomiting (OINV) 
3.  More p atie
nts treated with CL -108 5 mg experience complete absence of OINV 
than patients  treated with a comparable p roduct containing hydroc odone 5 mg/ 
acetaminophen  325 mg 
4.  Patients  treated w ith CL -108 5 mg experience less vomiting than patients  treated 
with a comparable product containing hydrocodone 5 mg/  acetaminophen  325 mg 
5. Patients treated with CL -108 5 m g experience less nausea than patients treated 
with a comparable product containing hydrocodone 5 mg/acetaminophen 325 mg 
6. Patients treated with CL -108 5 mg exper ience less nausea and vomiting than 
patients treated with a comparable product containing hydrocodone 5 
mg/acetaminophen  325 mg 
7. Patients treated with CL -108 5 mg exper ience less nausea and vomiting after 
discharge following surgery than patients treated with a comparable product containing hydrocodone 5 mg/acetaminophen 325 mg  
 
8. Patients treated with CL -108 5 mg take
  more doses over days 3 -7 and have 
greater reduction in pain and less OINV after discharge following surgery than 
patients treated with a comparable product containing hydrocodone 5 mg/ 
acetaminophen 325 mg  
 
9. Patients treated with CL -108 5 m g take more doses each  day over days 3- 7 and 
have greater reduction in pain and less OINV after discharge following surgery 
than patients treated with a comparable product containing hydrocodone 5 mg/ 
acetaminophen 325 mg. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 44 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Page 44  of 86 
 These labelling endpoints are supported by the co- prima ry and ke y  secondary endpoints. 
7.4.5 Study Populations 
Three datasets 
will be used for analysis: safety, intent -to-treat, and per  prot ocol.   
The definition of these populations follows: 
‚Ä¢ Safety Population:  All randomized patients  who received at least one dose of 
study medication comprise  the Safety Population. 
‚Ä¢ Intent- to-Treat (ITT) Population:  All randomized patients  who took at  least one 
dose of study medication compris e the Intent -to-Treat  Population.  The ITT 
Population is the same as the Safety Population. 
ÔÇß Per-Protocol Population:  All ITT patients  without major protocol  violations that 
significantly affect the efficacy analyses.   (Major and minor  protocol violations 
will be defined in the SAP.) 
Safety will be analyzed based on the safety population. E fficacy will be  analyzed based 
on the ITT and Per-Protocol populations. 
7.4.6 Predefined Subgroups 
Analgesia (S
PID 24, SPID 48) will be analyzed in the subgroups of  patients with moderate 
pain an d patients with severe pain . No other subgroup a nalyses are planned.   
7.4.7 Missing Data Conventions  
Missing dat
a for PI -NRS, NS, VFS  and O SS will be  imputed on a patient -by-patient 
basis as specified in the Statistical Analysis  Plan.  
7.4.8 Use of Supplemental Medication 
After eac
h use of the supplemental medication for pain (ibuprofen) during the  48-hour 
period of t
he primary outcome measures, a baseline observation carried forward (BOCF) 
method w ill be used to impute PI -NRS  and a worst observation carried forward (WOCF) 
method will be used to impute NS, V FS, and OSS  values for the next 6 hours (the 
duration of action on the label for ibuprofen 400 mg). After the first use of anti -emetic 
medication, a worst observation carried forward (WOCF) method will  be used to impute 
NS, VFS , and OSS values (because any use of an anti -emetic indicates the presence of  
OINV, i.e., non-response), and a baseline observation carried forward (BOCF)  method 
will be used to impute PI -NRS values  until the next scheduled assessment following the  
duration of action of the anti- emetic medication.5,9 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 45 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Pag e 45 of 86 
 7.4.9 Statistical Analysis  
All analys e
s will follow a prospectively approved statistical analysis plan  (SAP). The 
S
AP will be approved before data lock  and before any looks at  the data. The SAP will 
include the details of all analyses, all database specifications and convent ions, and all 
tables, listings and figures.  
All analyses will be conducted using two- sided tests  w ith a type I error of 0.05. 
7.4.10 Descriptive Statistics:  
Continuous vari
ables will be summarized as n, mean, standard deviation, minimum, 
median, a
nd maximum. Asymptotic 95% confidence intervals for  means and for mean 
differences will be provided as specified in the SAP. For  variables expected to be 
skewed, transformations such as log may be specified in the SAP. Categorical and binary variables will be summariz ed as percenta
 ges, noting  the 
numerator and denominator of the percentage. 
7.4.11 Analysis of the OINV Co -Primary E ndpoint: 
The OINV endpoint will be tested using a logistic regression model with  treatment, 
gend
er, and investigator as main effects. Treatment will  be tested using a type III 
likelihood ratio test. The test will be performed on the ITT  population. 
7.4.12 Analysis of Analgesia Co-Primary Endpoint: 
The analgesia 
endpoint will be tested using a general linear model with  treatment, 
inve
stigator and gender  as ma in effects. Treatment  will be tested using a type III test. The 
test will be performed on the ITT  population. 
The mean difference between treatment groups will be calculated using least  squares 
means,
 and 95% confidence interval will be calculated.  
7.4.13 Sensitivity Analysis of Primary Endpoints  
The missing
 data imputation method  has little impact on the event driven OINV 
endpoint. Therefore, no sensitivity analysis will be performed for the OINV endpoint.  
Two sensitivity analyses will be performed on SPID 48 to evaluate the robustness of the 
co-primary analgesic efficacy analysis and the impact of missing data on the results for 
the ITT population. 
In the first sensitivity analysis, the method of multiple imputations (MI)10 will be used to 
impute post -dose missin g pain intensity difference s over 48 hours (either due to early 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 46 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIAL  Pag e 46 of 86 
 discontinuation, no valid data entry, or use of supplem e ntal medication for pain or use of 
anti-emetic s for the duration of their dosing interval during  which  the medications  were  
administered ) by using Markov chain Monte Carlo (MCMC) method  for the non-
monotone missing pattern values and then the sample mean pain intensity difference  for 
patients  with available data within that treatment group at that time point for the 
monotone missing patter n values . The method of multiple imputations uses SAS PROC 
MI to generate multiple complete datasets  for the calculation of SPID 48, and PROC 
MIXED  and MIANALYZE  to analyze and combine the results from them. To ensure 
robustness of results 10 complete datas ets will be created  with the initial seed value set at 
‚Äò123‚Äô. The same general linear  model for the co -primary efficacy endpoint will be carried 
out for the above datasets. 
In the second sensitivity analysis, a Pattern Mixture Model ,11 which is based upon an 
assumption of 
Missing Not at Random (MNAR)  with an approach similar to above 
multiple imputations , will be used with missing data for Patients  at each time point 
imputed using the available data for Placebo Patients  at that time point.  
7.4.14 Analy ses of Key S econ dary Endpoints: 
The details of  key seconda ry endpoint analyses will be specified in the SAP.   
7.4.15 Statistical Significance:  
The two co -pri
mary end points will each be tested at the 0.05 using a two- sided test using 
the ITT  population. Both co- primary endpoints must be statistically significant so that no 
adjustment for multiple comparisons is required.  If both co -primary nau
 sea and pain endpoints are significant, the key  secondary 
endpoints will be tested using Hochberg step -up test procedure for  controlli ng family -
wise type 1 error on the ITT population at the 0.05 level. This sequential testing 
procedure preserves the overall type I error so that no adjustment for multiple tests is 
required.   
7.4.16 Safety 
Adverse ev
ents will be summarized for each treatment gr oup. Tabulations a nd listings of 
values and/or parameters will be presented for the incidence and severity of adverse 
events  (and, separately, for the incidence and severity of  nausea, retching, vomiting, 
emetic epi sodes, sleep disturbance, headache).   
7.4.17 Interim Analyses  
An indepen
dent Data Monitoring Committee (DMC) will meet to review efficacy and 
safety endpoi
nts. The DMC will operate under a charter and will make recommendations 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 47 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 47 of 86 
 to the sponsor. An interim analysis will be performed by the DMC after approximately 
66% of the subj e
cts have completed the 300 -subject study and there is adequate 
representation from each of the investigative sites (i.e., approximately 30 completed subjects per site).   If it is judged impossible to achieve this de  minimis representation at a 
particular site or sites, the interim analysis will be conducted on the total number of subjects completed (i.e., approximately 200 subjects). Since the DMC will review 
efficacy data, formal sequential boundaries for efficacy and futility will be declared in the 
DMC‚Äôs Statistical Analysis Plan.   
7.4.18 Protocol D eviation s 
No
 patients  will b e excluded from the Safety or Intent -to-Treat populations because of  
protocol violations. Patients  who do not meet admission criteria prior to dosing or who 
have major protocol violations after dosing that could significantly affect  efficacy results 
(e.g., a missed dose of study medication)  will be excluded from the Per Protocol 
population.  
Minor protocol deviations  that do not bias efficacy results (such as  assessment s not 
obtained at scheduled  time p oints during the 48-hour primary treatment evaluation 
period) will not be noted as deviations. 
8 Clinical Supplies  
8.1 Packaging 
Doubl
e-blinded 
study medication will be provided in 100-mL HDPE bo ttles, each  
containing 45 capsules of study medication. 
8.2 Label 
On the outer c
over of each bottle will appear:  
Subject Initials /Subject S creening Number :           ___ ___ ___ /___ ___ ___ 
Date Dispensed:  ___ ___ ___   
Protocol
 Number:   CLCT -018 
 
Direc
tions:     Take one capsu le every 4 -6 hours for pain.   
   Do not exceed  6 capsules in a 24 -hour period.   
     Keep this out of the sight and reach of children.  
Contents:   45 green capsule s   
   Store at 2
 0o to 25oC (680 to 770F) 
  
Manufactured for: Charleston  Laboratories  
   1001 North US Highway 1  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 48 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 48 of 86 
    Jupiter , F L 33477 
 
Date of Manufacture:  MM- DD-YYYY  
 Lot #:  
  vvvvvvv 
 Caution:   New Drug  Limi
 ted by Federal Law to Investigational Use 
Only  Federal law prohibits the transfer of this drug to any 
person other than the patient for whom it was prescribed.   
Investigational Drug to be used by a Qualified Investigator Only.  
 Study Medication #:  XXXX  
 
A tear -off label  will also be
  attached to  the outer cover of each bottle and will be placed in the 
source documents.  The top section of the tear- off label is open- label : 
 Subject Initials   ___ ___ ___  
Subject 
Screen #  ___ ___ ___ 
Date  ___ ___ ___ 
Study 
Medi
cation #  XXXX  
 
The bottom
 portion of the tear -off label  is scratch -off (blinded, identifying the Study Medication 
# and the Treatment G roup). 
 
9 Investigator Obligations  
9.1 Adverse Event
 Report ing Obligations 
An important objective  of this stud y is to assess the safety and tolerability of the drug.  
Therefore, the Investigator  is responsible for recording and reporting adverse events observed 
during and after study drug treatment. 
9.1.1 Definition of an Adverse Event 
An 
adverse event is any reaction, side effect, or other untoward event, regardless of 
relationshi
p to study drug, including death, experienced by a patient .   An adverse event 
may consist of a disease, an exacerbation of a pre- existing illness, or condition, a 
recurrence of an intermittent illness or condition, a set of related signs or symptoms, or a 
single sign or symptom. 
Serious and non- serious eve nts occurring a fter the ICF  is signed, but prior to first dose of 
study drug , will be collected as part of the medical history. Adverse events noted or 
reported from the first administration of investigational product to Visit 3 will be 
followed until resolution. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 49 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 49 of 86 
 A treatment -emergent  adver s e event (TEAE) is defined as: 
1. Any new medical occurrence not seen before initial study drug administration.  
2. A pre -existing medical condition which recurs with increased intensity o r 
increas
ed frequency subsequent to initial study drug administration. 
3. A medical condition which is present at the time of study drug administration 
which ex
acerbates at any time following initial study drug administration.  
A pre -existing condition or s igns or symptoms present at the time of study drug 
administration are not  considered an adverse event unless criterion #2 or #3 above 
applies.  Signs or sympt oms associated with the disease or medical condition being 
evaluated (e.g., pain) should not be re corded as adverse events.  
Standard symptoms expected in patients  who have recently undergone first metatarsal 
bunionectomy will not be recorded as adverse event s unless they are of greater severity 
and/or intensity than would be expected.  The events considered standard in this study 
are:  pain, erythema, numbness, swelling, bruising, bleeding, and decreased range of 
motion of the affected foot.  Investigators will use their clinical judgment in determining 
whether these symptoms are of greater severity than usual.    
9.1.2 Definition of a Serious Advers e Event (SAE)  
Each of the following adverse event s is defined as serious:  
1. Death  
2. Life-threatening event  
A "life -thr
eatening" event is present when the patient  was , in the view of the 
Investigat or, at immediate risk of death from the event as it occurred.  Note that 
this definition does not include an event that, had it occurred in a more serious 
form, might have caused death. 
3. Inpatient hospitalization or prolongation of existing hospitalization 
Note that 
elective hospitalization for treatment of a pre -existing condition that did 
not worsen/exacerbate during the study is not considered a serious adverse event.  
Complications, which occur during any hospitalization, are adverse events and if 
such complication(s) prolongs the hospitalization, the event is a serious adverse 
event.  These conditions should be recorded on the physical examination section of the eCRF.  
4. A persistent or significant disability / incapacity  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 50 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 50 of 86 
 5. Any con genital ano ma ly / birth defect  
6. Important medical events that may not be immediately life -threatenin g or result 
in death or hospitalization may be considered a serious adverse event (SAE) 
when, based upon appropriate medical judgment, they may jeopardize the patient  
or may require medical or surgical intervention to prevent one of the outcomes listed in the definition of SAE above.   
Examples of such medical events include allergic bronchospasm requiring 
intensive tr
eatment in an emer gency room or at home, blood dyscrasias, or 
convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
9.1.3 Recording and D ocumentin
 g Adverse Events  
Patient -reported a dverse even ts will be captured from the initial time of dosing with study 
medication , through the time of  discharge from the study . Serious adverse events will be 
captured from the initial time of dosing with study medication until 30 days after the last 
time of dosing with study medication.    
Each adverse event mu st be promptl y recorded and sufficiently documented by the 
Investigator in the source document as well as the eCRF, even if the adverse event is 
assessed by the Investigator  as unlikely to be causally related to therapy with study drug.  
The Investigator s hould attempt, if possible, to establish a diagnosis based on the 
presenting signs and symptoms.   
If the adverse event meet s the definition of an SAE, in addition to being documented on 
the AE page of the eCRF, the SAE form must also  be completed. The completeness and 
accuracy of these forms will be monitored.  
When a  patient  spontaneously  mentions any problems  or an adverse event is observed, the 
duration and intensity  of each adverse event will be documented as well as any action 
taken and treatment ad ministered.  The investigator will evaluate the adverse event and 
determine  the severity and relationship to (association with) study medication.   
Recurrent symptoms of a chronic pre -existing condition are not considered adverse events 
unless they occur in a worse or unexpected pattern during study drug administration. 
9.1.4 Intensity of Adverse Events  
The intens
ity (or severity) of adverse events is characterized as mild, moderate, or 
severe:  
‚Ä¢ Mild  adver
se events are usually transient, do not interfere with the patient ‚Äôs dai ly 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 51 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 51 of 86 
 activities , and often respond to symptomatic therapy (e.g. rest or distraction). 
‚Ä¢ Moderate  adv
erse events introduce some level of inconvenience or concern to 
the patient  and may interfere with daily activities, but are usually ameliorated by  
simple therapeutic measures  (e.g. medication to treat the symptom) . 
‚Ä¢ Severe adverse even ts significantly interrupt a patient‚Äôs usual daily activity and 
often are not ameliorated by therapeutic drug therapy or other treatment.  In 
addition, the adverse event may require discontinuing or reducing the dose of 
study medication administration.  
When the intensity of an adverse event  chan ges more frequently than once daily, the 
maximum intensity for the event is reco rded.  If the intensity  chan ges after a number of 
days, then these sub- events or chan ges are recorded separately (i.e., with  distinct onset 
and stop dates). 
9.1.5 Relationship to Study Medication 
The degree
 of ‚Äúrelatedness‚Äù of the adverse event to the study drug may be described 
using the 
following scale:   
‚Ä¢ Not related  indicates that the adverse event is definitely not related to the 
study drug. 
‚Ä¢ Unlikely related  indicates  that there are other, more likely causes and study 
drug is not suspected as a cause. 
‚Ä¢ Possibly related  indicates that a direct cause and effect relationship between 
study drug and the adverse event has not been demonstrated but there is a 
reasonable possibility that the event was caused by the study drug. 
‚Ä¢ Probably related  indicates  that there probably is a direct cause and effect 
relationship between the adverse event and the study drug.  
It is the sponsor‚Äôs policy to consider ‚ÄúProbable‚Äù and ‚ÄúPossible‚Äù causality assessments as 
positive 
causal ity and  to consider ‚ÄúNot‚Äù and ‚ÄúUnlikely‚Äù causality assessments as 
negative causality.  
Assessments will  be recorded on the eCRF .  The date and time of the l ast dose  of study 
medication  will be recorded on the AE page of the eCRF . 
9.1.6 Therapeutic Failure as an A dverse Event 
Reports of therapeutic failure need not be recorded or processed as adverse events.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 52 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
&+$5/(6721 /$%25$725,(6 ,1&
3URWRFRO1R&/&7

$XJXVW &21),'(17,$/ 3DJH RI
&RPSOLFDWLRQVRIWKHUDSHXWLFI DLOXUHVKRXOGEHUHFRUGHGDVDGYH UVHHYHQWV
7UHDWPHQW3HULRG
$GYHUVHHY HQWVRFFXUULQJIURPWKHLQLWLDOVWXG\GUXJDGPLQLVWUDWLRQWRWK HIROORZXS
9LVLWGLVFKDUJHVKRXOGEHUHFRUG HGDVDGYHUVHHYHQWVLQWKHH &5)
$OOXQUHVROYHGDGYHUVHHYHQWVREVHUYHGDWWKHIROORZXS9LVLW VKRXOGEHIROORZHGE\
WKH,QYHVWLJDWRUXQWLOWKHHYHQWVDUHUHVROYHGVWDELOL]HGW KHSDWLHQWLVORVWWRIROORZXS
RUWKHHYHQWLVRWKHUZLVHH[SODLQHG5HSRUWLQJRIVHULRXVDGY HUVHHYHQWVVKRXOGIROORZ
6HFWLRQ 
,QYHVWLJDWRU5HSRUWRID6 HULRXV$GYHUVH(YHQW
)RUDQ\6$(WKH,QYHVWLJDWRUP XVWILUVWFDOOWKH,1&0HGLFDO0 RQLWRU
0'DW
2IILFH 
&HOO FHOO 
(PDLO 
$1'ID[DQGRUHPDLOWKHUHSRUWWR,1&6DIHW\'HSDUWPHQWZLWKLQ KRXUVDIWHUWKH
,QYHVWLJDWRU¬∂VLQLWLDOLGHQ WLILFDWLRQRIW KHHYHQW
6$(5HSRUWLQJ)D[1XPEHU 
(PDLO 
,I'U FDQQRWEHUHDFKHGWKH,QYHVWLJDWRUVKRXOGFDOO 0'
DW&KDUOHVWRQ/DERUDWRULHV 
0'
&HOO 
(PDLO 
'DWDIRUWKH6HULRXV$GYHUVH(YHQWV)RUP0HGLFDO+LVWRU\ )RUP DQG&RQFRPLWDQW
0HGLFDWLRQ)RUPPXVWEHHQWHUHGLQWRWKHH&5)ZLWKLQKRXUVR IUHFHLSWRIWKH6$(
7KHVSRQVRUPXVWUHFHLYHDZULWWH Q6$(UHSRUWRIWKHHYHQWZLWK LQZRUNLQJGD\DIWHUWKH
,QYHVWLJDWRU¬∂VLQLWLDOLGHQWLILFDWLRQRIWKHHYHQW7KHFRPSOHW HGIRUPVKRXOGEH)$;('RU
(PDLOHGWRWKH,1&6DIHW\'HSDU WPHQWDWWKHQXPEHUVOLVWDERYH 
7KH,QYHVWLJDWRULVUHVSRQVLEOHIRUFRQWLQXLQJWRUHSRUWWRDQ\ QHZRUUHOHYDQWIROORZXS
LQIRUPDWLRQRQWKHDGYHUVHHYHQWDVWKHLQIRUPDWLRQEHFRPHVNQR ZQWRWKH,QYHVWLJDWRU
7KH,QYHVWLJDWRULVUHTXLUHGWRQRWLI\WKH,5%RIDOO6$(VRFFX UULQJDWKLVKHUVLWHZLWKLQD
UHDVRQDEOHWLPHSHULRGRUDVJRYHUQHGE\WKH,5%&KDUOHVWRQ/DERUDWRULHV,QF
3URWRFRO1XPEHU&/&7&OLQLFDO6WXG\5HSRUW)LQDO
1RY
&RQILGHQWLDO 3DJHRIBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBPI
PI
PI
PI
PI
PI
PI PI
PI
PI
PI
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 53 of 86 
 9.1.9 Other Investiga tio ns 
The Investigator and supporting  personnel responsible for patient  care should institute 
any supplementary investigations of serious adverse events based on their clinical 
judgment of the likely causative factors.  This may include seeking a consult by an 
appropriate specialist.  Charleston Laboratories  may also request extra tests or follow -up 
assessment.  If a patient  dies, any post -mortem findings (including histopathology) must 
be provided to Charleston Laboratories . 
9.1.10 Ethics Committee Notific ation  
The Investigator  is respon sible for promptly notifying the ethics committee (Institutional 
Review Board) of all serious adverse events, including any significant follow -up 
information. 
9.1.11 Post-study Seri ous Adverse Events  
The Investigator should notify  Charleston Laboratories  of any new serious adverse event 
that occurs within 30 days following the last dose of study drug.   
Investigator s should notify  Charleston Laboratories , or designee, if the y become aware 
of a study participant who is one of the parents of a subsequently conceived child with a 
congenital anomaly.  
9.1.12 Regulatory A spects  
In ag
reeing to the provisions of this protocol, the legal responsibilities for prompt 
notificati
on of serious ad verse events are accepted by the Investigator. 
9.2 Drug Accountab ility 
9.2.1 Storage of Investigatio nal Drug 
All study medication for this study must be stored under ambient temperature conditions 
in a locked ar
ea suitable for schedule II controlled substances. The area must also be free 
of environmental extremes and with a limited access.  Before any agreements are 
concluded between the Principal Investigator and Charleston Laboratories , the drug 
storage area will be inspected and the drug accountability system discussed.  
9.2.2 Receipt of Drug S hipment  
No s
tudy drug will be shipped prior to receipt of a valid DEA Form 222 by the clinical 
trial suppl
ier. The Principal Investigator or designee, upon receipt  of the drug supplies  
and accompanying packing list , will conduct an inventory and sign the pro forma invoice 
and manufacturer shipping checklist and forward one copy to the manufacturer and one 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 54 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 54 of 86 
 copy to Charleston Laboratories .  One cop y  of all documents contained with the drug 
supplies must be retained in the Investigator 's records.  
9.2.3 Materials Control  
The 
Principal Investigat or, or his designee, shall record the dispensing of the clinical 
drug supply to patients  and any subsequent returns.  These records wi ll be made 
available to clinical monitoring personnel for the purpose of accounting for the clinical 
drug supply.  A drug supply inspection for inventory purposes and assurance of proper 
stora ge will be conducted no less than every 6- 8 weeks  throughout the  clinical 
investigation.  Any significant discrepancy and/or deficiency is to be recorded  and 
immediately  reported to Charleston Laboratories  and the DEA (according to 
requirements),  and a plan for resolution is to be documented. 
Clinical trial material must not be loaned or dispensed by the Principal Investigator to 
another Inve
stigator or site.  Only patients  in this clinical trial and eligible for treatment 
are to receive this clinical trial material.  
9.2.4 Return of Drug to Sponsor 
At the end of the stud y, a final inventory will be performed by the Study Monitor and the 
Principal Investigator  or designee.  If any supplies are missing, this must be indicated on 
the Drug Accountability F orm to gether with an explanation of the discrepanc y.  The 
Principal Investigator  will be instructed to return all unused medication to the 
manufacturer  along with a DEA 222 Form  and to return a copy of the Clinical Supplies 
Return Form  to Charleston Laboratories or designee .  The Principal Investigator  must 
retain a copy  of the Clinical Supplies Return Form and the original Drug Accountability 
Form .  A copy of t he Drug Accou ntability Form must be returned to the Study 
Monitor /Charleston Laboratories.  
9.3 Deviations from Protocol 
The Invest i
gator is not per mitted to deviate from the protocol .  Apart from the regulatory 
requirements, it is vital to the success of the study that the Investigator adheres to the details of 
the protocol and thus holds to a minimum the number of cases later classified as "incomplet e," 
"unusable," or "not evaluable." 
Charleston Laboratories  will not c ompensate the Investigator for evaluation of cases in which 
the procedures and evaluations are not conducted as specified in  the protocol. 
9.4 Disclosure of Data 
9.4.1 Confide
ntiality  
The Princ
ipal Investigat or and all of the Principal Investigator 's employees or a gents 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 55 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 55 of 86 
 involved with this study shall not disclose or use for any purposes (other than 
performan c
e of the Study) any data, records, or other information (hereinafter 
collectively "Information") disclosed to the Principal Investigator  or his employees or 
agents.  Such Information shall remain the confidential and proprietary property of 
Charleston Laboratories , and shall be disclosed only to the Principal Investigator or his 
employees or a gents.   
The obligation of non-disclosure shall not apply to the following: 
a. Information after such time that it is or becomes publicly available through no 
fault of  
the Principal Investigator  or his employees or a gents; 
b. Information after such time that it is  disclosed  to the Principal Investigator by a 
third party entitled to disclose such information; or 
c. Information that is already known to the Principal Investiga tor as shown by his 
prior written records provided the Principal Investigator  so advises Charles ton 
Laboratories  within twenty (20) days after disclosure of the Information to the 
Principal Investigator by Charleston Laboratories . 
9.4.2 Publication  
All data
 resulting from this study remain property of Charleston Laboratories.  
Publication 
of trial results is discussed in the Clinical Trial Agreement.  
9.5 Study Records and S o urce Documents  
Federal regulations and Charleston  Laboratories  policy require that, following completion of a 
clinical study, a copy of all records of that study be maintained by the Principal Investigator for 
at least the shorter of the following two time periods: 
‚Ä¢ Two years after FDA approval of the drug for the indication for which it was 
investigate
d; or 
‚Ä¢ In situations where no application is to be filed or an application is not approved for 
such indicat
ion, two years after the IND is discontinued and the FDA is notified. 
Current electronic data collection should be  maintained throughout the conduct of the study.  
The Investigator must maintain an electronic copy (e. g CDROM) of all data collected for each 
patient  screened and treated.  Charleston Laboratories or its representative  will provide the  
electronic copy of  the data;  paper copies of the completed eCRFs for each patient  are not 
required. 
In order to assure the accuracy of data collected in the eCRFs, it is mandatory that 
representati
ves of Charleston Laboratories , as well as representatives of the Food and Dr ug 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 56 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 56 of 86 
 Administration, have access to original source documents (e.g., patient  records, pat ient charts, 
and laboratory reports).  During the review of these documents, the anonymity of the patient  will 
be respected with strict adherence to professional standards of confidentiality. 
Charleston Laboratories  reserves th e right to terminate the study for refusal of the Investigator to 
supply source documentation of work performed in this clinical trial. 
9.6 Investigator D ocumenta tion 
9.6.1 Patient C onsent  
Writte
n informed co nsent of the  patient  to participate in the study must be obtained in 
accordance with the Declaration of Helsinki and in accordance with the FDA 
Regulations set forth in Part 50 of Title 21 of the Code of Federal Regulations. 
9.6.2 Ethics Committee Review  
This
 protocol, the Informed Consent Form , and any re levant supporting information must 
be submitted to the ethics committee (IRB) for review and must be approved before the 
study is initiated. In addition, all advertising materials  must be approved by the IRB. Th e 
study will be conducted in accordance with FDA Regulations, applicable national and local health authority, and IRB requirements.  
The Principal Investigato
 r is responsible for keeping the IRB apprised of the progress of 
the study and of any chan ges made to the protocol as deemed appropriate.  
The Principal Investigat or must also keep the IRB informed of any significant adverse 
events.  Investigator s are requi
 red to promptly notify their respective IRB of all adverse drug 
reactions that are both serious and unexpected. This generally refers to SAEs that are not 
already identified in the Investigator Brochure and that are considered by the Investigator 
to be possibly or probably related to the study drug. Some IRBs may have other specific 
adverse event requirements to which Investigator s are expected to adhere. Investigator s 
must immediately forward to their IRB any written safety report or update provi ded by 
Charleston Laboratories  (e.g. IND safety report, Investigator Brochure, safety 
amendments and updates, etc.). 
The Principal Investiga t or will forward to Charleston Laboratories  a copy of the ethics 
committee approval of this protocol, amendments, informed consent form and any 
chan ges to the informed consent  form .  A copy of the IRB membership list is to be 
provided to Charleston Laboratories .   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 57 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 57 of 86 
 9.6.3 Curriculum Vitae and FDA Form 1572 
The Pri n
cipal Investigat or must provide Charleston Laboratories  with his /her own 
current curriculum vitae, a current curriculum vita  for each sub-Investigator , and a 
completed and signed FDA Form 1572. 
9.6.4 Financial Disclosure   
The Inves
tigator is required to provide Financial Disclosure for each person listed on 
Form FDA 1572 r
elating to financial interests held.  
9.6.5 Tax ID No. and Form W-9 
Prior to 
payments from any grant -in-aid, Charle ston Laboratories  must be provided the 
tax identification number for each grant payee and a completed Form W -9.  In addition, 
the Investigator is required to provide Financial Disclosure for each person listed on 
Form FDA 1572 relating to financial interests held. 9.6.6 Laboratory C ertification
  and Normal Values  
(Not applicable.)  9.6.7 Final Report to the IRB  
Af
ter completion of the clinical trial, the Investig ato r will submit a Study Close- Out 
Report to the IRB. 
10 Termination of Study  
Charlesto
n Laboratories  reserves  the right to discontinue this study for administrative reasons at any 
time.  Investigator s will be compensated for reasonable expenses incurred, if it is necessary to 
terminate the study.  Charleston Laboratories  will not compensate the Investigator  for evaluation of 
cases in which the procedures and evaluations are conducted in a manner other  than that specified 
by the protocol. 11 Investigator's Protocol Agreement  
The Inves 
tigator's Protocol Agreement (last page  of this prot ocol) must be signed by the Principal 
Investigator .  The original or a copy must be kept on file at Charleston Laboratories  or designee, and 
the Investigator must retain the original or a copy.  The completed Investigator 's Protocol 
Agreement signifies review and acceptance of the protocol by the Principal Investigator prior to 
initiation of the study.  
 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 58 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 58 of 86 
 12 References  
1. Apfel  CC, Greim CA, Haubitz I et al. A risk score to predict the probability of 
postoperative vomiting in adults.  Acta Anaesthesiol Scand 1998;42:495-501. 
2. Apfel CC, Laara E, Koivuranta M, et al. A simplified risk score for predicting 
postoperative nausea and vomiting.  Anesthesiology 1999;91:693-700. 
3. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. NEJM 2004 June 10;350 (24):2441 -
51. 
4. Apfelbaum JL, Gan TJ, Zhao S, Hanna DB, Chen C. Reliability and validity of the 
perioperative opioid-related symptom distress scale. Anesth Analg 2004;99:699-709. 
5. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance 
for Industry. Analgesic Indications: Developing Drug  and Biological Products. 2014. 
6. Gan T, Meyer T, Apfel C, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2003;97:62‚Äì71. 
7. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006;102:1884-98.20. 
8. Gan TJ, Meyer T, PONV Consensus Panel: Christian A, Chung F, Davis P, Eubanks S, Kovac A, Philips B, Sessler D, Temo J, Tramer M, Watcha M. A consensus panel 
identification of risk factors for PONV.  Anesth 2002; 97:A19. 
9. Panel on Handling Missing D ata in Clinical Trials; National Research Council. The 
Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press.  
2010. 
10. Ratitch B and O‚ÄôKelly M. Implementation of Pattern Mixture Models Using Standard SAS/STAT Procedures. PharmaSug 2011 paper SP04. 
11. Little RJA. Pattern -Mixture Models for Multivariate Incomplete Data with Covariates. 
Biometrics, Vol. 52, No. 1 (Mar., 1996), 98-111 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 59 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 59 of 86 
 13 Appendices  
13.1 Appendix 1. A
nalgesic Rating  Scales  
 
Numerical Pain Intensity Scale (PI -NRS)  
 
 
 
On a scale of 0 to 10, where 0 is ‚Äúno pain‚Äù and 10 is ‚Äúsevere pain,‚Äù  circle 
the number that best describes your pain now . 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
 
Categorical Pain Intensity Scale (PI- CAT)  
 
 
 
How would you describe your pain now ? 
 
 (circle one)  
 
NO MILD  MODERATE  SEVERE  
PAIN  PAIN  PAIN  PAIN  
 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 60 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 60 of 86 
  
 
13.2  Appendix 2: Nausea/Vomiting Rating Scales  
 
Nausea Scale (NS)  
 
 
 
Over the past half-hour (over the past hour) , 
have you had any nausea  
(feeling like you wanted to throw up)?  
 
(circle one)  
 
NO NAUSEA    NAUSEA  
  
Vomiting Frequency Scale (V FS) 
 
    
    
How often did you vomit (throw up) over the past hour? 
 
  (Circle one)  
   
NOT           ONE          TWO  
   THREE OR 
AT ALL     TIME        TIMES         MORE TIMES  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 61 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 61 of 86 
  
 
13.3 Appendix 3: Opioid Symptoms Scales (OSS) 
 
 
For each sy mptom you‚Äôve had over the past 24 hours ,  
circle the number that describes how severe it was for  you: 
 
 
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 62 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 62 of 86 
  
13.4 Appendix 4.  Nausea Prone Questionnaire (called ‚ÄúHealth Questionnaire‚Äù in the  CRF)  
 
1. What medications have you used over the past week?  
 
Any antihistamines (e.g., Benadryl, Claritin)? Any cough -cold products (e.g., Sudafed, 
Tussionex)? Any antibiotics (e.g., Cipro, tetracycline)? Any vitamins or nutritional 
supplements (e.g., vitamin E, calcium)?  Any prescription medicines? 
 
List all medications used over the past week : 
 
 
 
 
 
2. Did you have any side effects from any of these medicines?  NONE  N/A 
 
(Circle all that apply)  
 
 
a) Nausea  b) Vomiting  
 
c)  Problems  with urination d) Diarrhea  
 
e)  Constipation f) Itchy  skin 
 
g)  Dizziness  (light- headed)  h) Difficulty  concentrating  
 
i) Feeling  confused j) Drowsiness  (difficulty staying  awake)  
 
k)  Lack of energy  (fatigue,  weakness)  l ) Dry  mouth 
 
m) Headache  n) Hives  
 
o) Other:     
 
p) Other:     
 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 63 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 63 of 86 
 Considering medications you have used in the past (e.g., antihistamines, cough medicines, 
cold products, a nt
ibiotics, nutritional supplements, prescription medicines), have you ever 
had any side effects from any  medicines?                          NONE  
 
(Circle all that apply)  
 
a) Nausea  b) Vomiting  
 
c)   Problems  with urination d) Diarrhea  
 
e)  Constipation f) Itchy  skin 
 
g)  Dizziness  (light- headed)  h) Difficulty  concentrating  
 
i) Feeling  confused j)  Drowsiness (difficulty staying  awake)  
 
k)   Lack of energy (fatigue,  weakness)  l ) Dry  mouth 
 
m) Headache  n) Hives  
 
o) Other:     
 
p) Other:     
 
 
Write the medicine(s) beside each side effect:  
For example:  Drowsiness ‚Äì Benadryl, Tylenol with codeine, Vicodin. 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 64 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 64 of 86 
  
3. Have you ever used a strong pain- killer, a  prescription  drug NO YES  
such as Vicodin, Oxycontin, Norco, Tylenol with codeine, morphine, 
Demerol, hydrocodone, Lortab, cough medicine containing codeine, Tussionex? 
 
Which  medicine(s)?     
 
 
 
4. Have you ever had any allergies or side effects from any of these medicines?   NONE  N/A 
 
(Circle all that apply)  
 
a) Nausea  b) Vomiting  
 
c)   Problems  with urination d) Diarrhea  
 
e)  Constipation f) Itchy  skin 
 
g)  Dizziness  (light- headed)  h) Difficulty  concentrating  
 
i) Feeling  confused j) Drowsiness  (difficulty staying  awake)  
 
k)   Lack of energy (fatigue,  weakness)  l ) Dry  mouth 
 
m) Headache  n) Hives  
 
o)  Other:     
 
 
 
Write in the medicine(s) beside each side effect:  
For example:  Drowsiness ‚Äì Tylenol with codeine, Lortab, Vicodin. 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 65 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 65 of 86 
  
 
6. Have you ever had an operation or surgical  procedure?  
If yes, type of operation or surgical procedure ( e.g., stitches): NO YES   
 
7. Were you ever nauseous after taking any medication  after the 
surgery or procedure?   
NO  
YES   
N/A 
8. Did you vomit after taking any medication after the surgery  or 
procedure? NO YES  N/A 
9. Do you have anemia or  bleeding  problems? 
If yes, medications you are  taking: NO YES   
 
10. Do you have heart disease or high blood pressure? 
If yes, medications you are  taking:  
NO  
YES   
 
11. Do you have asthma?  
If yes, medications you are taking:  
NO  
YES   
 
12. Do you have any gastro-intestinal disorders (ulcer, colitis,  etc.)? 
If yes, medications you are  taking:  
NO  
YES   
 
13. Do you have arthritis?  
If yes, medications you are taking:  
NO  
YES   
 
14. Do you have any endocrine disorder (thyroid disease,  diabetes)?  
If yes, medications you are  taking:  
NO  
YES   
 
15. Do you have any neurologic disease (seizure  disorder)? 
If yes, medications you are  taking:   
NO  
YES   
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 66 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 66 of 86 
  
16. Do you ever get ‚Äúvertigo‚Äù (a sense of  motion  when 
you‚Äôre not moving, a sense of things moving around you, 
with dizziness, lightheadedness, or loss of balance)?  NO YES  
17. Do you have ‚ÄúMeniere‚Äôs Disease‚Äù (a sense of the room spinning 
around you, ringing in the ears, hearing loss, ear  fullness, 
with recurrent bouts of dizziness, loss of balance, or unsteadiness)? NO YES  
18. Are you ever nauseous when you have a Meniere‚Äôs  attack?  NO YES  N/A 
19. Do you get ‚Äúmigraine  headaches‚Äù?  NO YES  
If yes, medications you are  taking:     
 
 
 
20. Do you ever get headaches that are associated  with nausea  NO YES       N/A 
or vomiting? 
 
21. Do you ever  get nauseous? NO YES  
If yes,  when?   
 
 
 
22. Do you ever get ‚Äúa knot in your stomach‚Äù when you‚Äôre  nervous  NO YES   
or afraid or very worried about something?  
 
23. Did this ‚Äúknot in your stomach‚Äù ever make you feel nauseous?  
 
NO  
 
YES   
 
N/A 
24. Did this ‚Äúknot in your stomach‚Äù ever make you  vomit?  NO YES  N/A 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 67 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 67 of 86 
 Following are questions about different situations where some people tend to be nauseous or 
vomit:  
 
25. Do you walk slowly or turn slowly to avoid losing your  balance?  NO YES  
26. Do you get ‚Äúcar  sick‚Äù?  NO YES  
27. Do you need to have the window open when riding in a car? NO YES  
28. Do you get ‚Äúsea sick‚Äù?  NO YES  
29. Do you get sick to your stomach or nauseous or even  vomit 
when you gag on something? NO YES  
30. Do you get sick to your stomach or nauseous or even  vomit 
when riding backwards on a train?  NO YES  
31. Do you get sick to your stomach or nauseous or even  vomit 
when riding on a plane during turbulence or a sudden turn? NO YES  
32. Do you get sick to your stomach or nauseous or even  vomit 
on roller coasters or other amusement park rides?  NO YES  
33. Do you get sick to your stomach or nauseous or even  vomit 
from spinning around? NO YES  
34. Do you get sick to your stomach, nauseous, or vomit sometimes 
when you bend over?  NO YES  
35. Do you get sick to your stomach or nauseous or even  vomit 
from seeing a frightening  movie? NO YES  
36. Do you get sick to your stomach or nauseous or even  vomit 
from seeing  blood? NO YES  
37. Do you get sick to your stomach or nauseous or even  vomit 
from seeing body parts (such as seeing a horrible accident)?  NO YES  
38. Do you get sick to your stomach or nauseous or even  vomit 
from seeing severe malnutrition (such as starving  children)? NO YES  
39. Do you get sick to your stomach or nauseous or even  vomit 
from smelling a very bad smell (such as  vomit)?  NO YES  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 68 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 68 of 86 
 40. Do you get sick to your stomach or nauseous or even  vomit 
from seeing someone throw  up? NO YES  
 
41. Do you get sick to your stomach or nauseous or  even  vomit 
after eating certain  foods? NO YES  
42. Do you get sick to your stomach or nauseous or even  vomit 
just thinking about getting  nauseous?  NO YES  
 
43. Think of situations where you tend to get sick to your stomach, nauseous or vomit 
 
--- such as taking a strong pain -killer or a cough medicine with codeine, gagging, 
riding a roller coaster, spinning around, turning around suddenly, riding in a car, 
sitting backwards on a train, riding in a boat, seeing blood, smelling a bad smell. 
 
In general:  
 
Do you consider yourself prone (likely) to get nauseous? 
 
(Circle one number) 
 
 
0 1 2 3 4 5 6 7 8 9 10 
NOT  VERY  
LIKELY  LIKELY  
 
 
 
44. Is there anyone in your family who has a tendency to get nauseous easily?  NONE  
 
Circle all relatives who are likely to get nauseous:  
 
FATHER  MOTHER  SISTER  BROTHER  TWIN 
UNCLE  AUNT  COUSIN  
45. Is there anyone in your family who gets nauseous after taking a strong pain killer 
(a prescription drug such as Vicodin, OxyContin, Tylenol with codeine, 
morphine, hydrocodone, Norco, Lortab, cough medicine containing codeine,  Tuss
 ionex)?  NONE  
 
Circle all  relatives who are prone to get nauseous after taking a strong pain killer: 
 
FATHER  MOTHER  SISTER  BROTHER  TWIN  
UNCLE  AUNT  COUSIN  
 
 
 
   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 69 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 69 of 86 
 14 INVESTIGATOR'S PROTOCOL AGREEMENT  
  
PROTOCOL NUMBER  CLCT -018 (Version 3.0) 
PROTOCOL TITLE  A Randomized, Double -Blind, Placebo - and Active -
Controlled Study to Determine the Efficacy and Safety of 
CL-108 5 mg (Hydrocodone 5 mg/Acetaminophen 325 
mg/Promethazine 12.5 mg) as a Treatment for Moderate -
to-Severe Pain and the Prevention of Opioid- Induced 
Nausea and Vomiting (OINV) following Orthopedic 
Surgery  
  By my signature, I confirm that my staff and I have carefully read and understand this protocol, and a
gree to comply with the conduct and terms of the study specified herein.  In 
particular, I/we have agreed to:  
 1. Maintain confidentiality and assure security of Charleston Laboratories , Inc. confi
 dential 
documents such as the protocol, case report form, Investigator 's Brochure, final study reports, 
manuscript drafts, unpublished data, correspondenc e, etc.  
 2. Assure access by Charleston Laboratories , Inc. monitor
 s to original source documents. 
 3. Retain IRB approval of
  study, any amendments to the study, and periodic re -approval as 
required.  4. Keep the IRB informed of
  serious adverse events.  A copy of the Study Close- Out Report  
will be sent to the IRB upon completion of the study.  5. Obtain written informed consent from each participant or their legal representative.  6.  Make prompt reports of serious adverse events to Charleston Laboratories, Inc.  
 7. Cooperate fully with any study -related G
 CP audit as performed by the sponsor's quality 
assurance group.  
 8. Abide by stipulations in the Disclosure of Data section.  9. Abide by manuscript preparation/authorship guidelines established at the outset of the study.  
  
   
Principal Investigator   Date  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 70 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 70 of 86 
 15 Protocol Amendment  1: Table of  C hanges  
Section Updated  Original Text/Content  Updated Text/Content  
Title Page and Footers  
Dates and Version #  Original Text  
Version 1.0, May 10, 2017 Updated Text:  
Version 2.0, June 16, 2017 
Retching Vomiting Index  
(RVI) Replaced with 
Vomiting Frequency Scale 
((VFS)  
Page 5 : Abbreviations  
Page 8 and 9 : Section 1.3 , 
Study Design  
Page 1 1: Section 1.8, Study 
Flow Char
t  
Page 1 5-17:  Section  4.2, 
Visit 2  
Page  22: Section  5.5 Use  of 
Supplemental ( Rescue) 
Medications, Paragraphs 6 -
9. 
Page 23:  Section 5.6, 
Withdraw
al 
Page 26 : Section 6.2.4, 
Retching
 and Vomiting 
Index (entire section 
replaced)  
Page 32: Section 6.3.4, 
Post-Surg
ical Eligibility 
Assessments and Dosing , 
#2  
Page 32-33: Sections 6.3.5, 
6.3.6, 6.3.7, 6.3.8 (Time 
Po
int Assessments)  
Page 43: Section 7.4.7, 
Missing 
Data 
Page 43: Section 7.4.8, Use 
of Suppleme
ntal 
Medications  
Page 62:  Section 13.2, 
Nausea/
Vomiting Rating 
Scales  Original Scale  
Retching Vomiting Ind ex 
(RVI)  
Section 5.6 Original Text 
For the RVI - Did you have 
these stomach symptoms over 
the past hour ? 
 Deleted  Scale  
RVI in all relative locations . 
Added Scale   
Vomiting Frequency Scale 
(VFS)  
General Changes  
-The entire RVI scale was 
replace with the VFS scale in all referenced sections.   
-The Acronym ‚ÄúRVI‚Äù was 
replaced w
ith ‚ÄúVFS‚Äù in all 
referenced areas of the protocol.  
-Timing of assessments of the 
new VFS 
scale will occur at the 
same time points specified for 
RVI in the original protocol.  
Section 5.6 Updated Text  
For the RVFSI ‚Äì How many 
times did you vomit (throw 
up) over the past hour ? Did 
you have these stomach 
symptoms  over the past hour ? 
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 71 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 71 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Nausea Inte nsity Scale  
Page 5 : Abbreviations  
Page 7 and 8: Section 1.3 , 
Study Design  
Page 1 1: Section 1.8, Study 
Flow Char
t  
Page 1 5-17: Section 4.2, 
Visit 2  
Page  22: S
ection 5.5, Use 
of Supplem
ental (Rescue) 
Medications, Paragraphs 6 -
9. 
Page 2 3: Section 5.6, 
Withdr
awal  
Page 2 6: Section 6.2.3 : 
Nausea Int
ensity Scale  
Page 32: Section 6.3.4 : 
Post-Surg
ical Eligibility 
Assessments and Dosing, 
#2 
Page 36-38: Sections 6.3.5 , 
6.3.6, 6.3.7 and 6.3.8  
(Assessmen
t Time points) 
Page 59: Section 13.2 
Nausea/
Vomiting Rating 
Scales  Original Name  
Nausea Intensity Scale (NIS) 
Original Definition  
Nausea Intensity Scale (NIS), 
a 0-10 Likert scale derived 
from the Edmonton Symptom 
Assessment Scales,5,7 to assess 
the intensity of nausea 
Section 5.6 Wording  
For the NIS - On a scale of 0 
to 10, where 0 is ‚Äúno nausea‚Äù 
and 10 is ‚Äúsevere nausea,‚Äù circle the number that best describes the worst nausea you‚Äôve had over the past half hour . 
 Update Name of Scale:  
Nausea Intensity  Scale  (NIS) 
Updated Definition :  
Nausea Intensity  Scale (N IS), a 
0-10 Likert binary scale derived 
from the Edmonton Symptom 
Assessment Scales,5,7 to assess 
the intensity  presence/absence of 
nausea 
Reference #5 and 7 in original 
protocol now deleted. 
 
Section 5.6 Updated Language  
For the NS - For the NIS - On a 
scale of 0 to 10, where 0 is ‚Äúno 
nausea‚Äù and 10 is ‚Äúsevere 
nausea,‚Äù circle the number that 
best describes the worst nausea 
you‚Äôve had Over the past half -
hour, have you had any nausea 
(feeling like you wanted to 
throw up)?  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 72 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 72 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Secondary Endpoints  
Page 9: Section 1.4.2 Key 
Secondary Endpoints Original Text  
1) Severity of opioid -induced 
nausea over 48 hours, 
comparing CL-108 5 mg 
to hydrocodone 5 mg/APAP 325 mg Updated Text:  
1) Absence of any Severity of 
opioid-induced nausea or 
any use of anti -emetic 
medication  over 48 hours, 
(complete absence of 
OINV) , comparing CL-108 5 
mg to hydrocodone 5 
mg/APAP 325 mg 
Added Secondary End Point 
#3:  
Percentage of patients without any nausea over 48 hours, comparing CL-108 5 mg to 
hydrocodone 5 mg/APA P 325 
mg  
Added Secondary End Point  #4 
Percentage of patients without any nausea or vomiting 48 hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
Secondary Endpoints  
Page  42:  Section 7.4.3 Key 
Secondary Endpoints Original Text  
1. Severity of opioid -
induced nausea over 48 hours, comparing CL -108 
5 mg to hydrocodone 5 mg/APAP 325 mg 
2. Percentage of patients with any 
vomiting over 
48 hours, comparing CL-108 5 mg to hydrocodone %5 mg/APAP 325 mg  Updated Text  
1. Percentage of patients with complete absence Severity  of 
OINV (no nausea, no vomiting, and no use of anti- emetic 
medication) opioid induced 
nausea over 48 hours, 
comparing CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 
mg 
2. Percentage of patients 
without any vomiting over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
ADDED #3  
Percentage of patients without 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 73 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 73 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
any nausea over 48 hours, 
comparing CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 
mg  
ADDED #4  
Percentage of patients without any 
nausea or vomiting 48 hours, 
comparing CL -108 5 mg to 
hydrocodone 5 mg/APAP 325 mg  
Rescue Medication 
Clarification 
 
Page 16: Section 4.2: Visit 
2 
 
Page 17: Section 4.3: 
Outpatient  Original Text  
Section 4.2: NA 
 
 
 Added Text  
Section 4.2 
All patients will receive a bottle 
of ibuprofen
 tablets (analgesic 
rescue medication) and a prescription for an anti -emetic 
of the investigator‚Äôs choice (anti -emetic rescue medication) 
to be used as needed during Study Days 3 -7. 
Section:  
The patient will be discharged from Visit
 2 with a bottle 
containing the remaining study 
medication capsules, a bottle 
containing ibuprofen 200 mg tablets (to be used  if needed), 
and a prescription for an anti-emetic( to be used  if needed).
 
 
Page  17: Sectio n 4.3 : 
Outpatient  Original Text  
to document any symptoms 
(adverse events) they 
experienced and any cigarettes 
smoked over the past 24 hours.  Deleted Text  
to document any symptoms 
(adverse events) they experienced  and any cigarettes 
smoked over the past 24 
hours.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 74 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 74 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Page 1 2: Section 2 : 
Background and Rationale   Original Text:  
‚Ä¶ the occurrence of any 
vomiting or use of anti- emetic 
medication (indicative of nausea) over 48 hours. 
‚Ä¶ 48 hours (SPID
48) will be 
compared for patients treated 
with CL -108 5 mg and those 
treated with placebo.   
Opioid Symptoms Scales 
(OSS), deri
ved from the 
Symptom Distress Scale to identify other opioid effects ,
4  
 Added Text:  
‚Ä¶.the occurrence of any vomiting or use of anti- emetic 
medication (indicative of nausea) over 48 hours.  The occurrence 
and frequency of vomiting will 
be measured on a 0- 3 Vomiting 
Frequency Scale, the 
occurrence of nausea will be measured on a binary Nausea Scale, and the use of anti- emetic 
medication will be documented in diaries.   
‚Ä¶. 48 hours (SPID
48) will be 
compared for patients treated with CL -108 5 mg and those 
treated with placebo.  Pain 
intensity will be measured on a 
0-10 Pain Intensity Numerical 
Rating Scale.  
Opioid Symptoms Scales (OSS), 
derived from the Symptom 
Distress Scale to identify other 
opioid effects,4 which were used 
in CLCT -002 and C LCT -003 
Page  18:  Inclusion 
Criteria, #2 Original  Text  
‚Ä¶condom, abstinence or surgical sterilization)‚Ä¶  Updated Text  
‚Ä¶condom, abstinence  abstain 
from heterosexual sex, or 
surgical sterilization)‚Ä¶  
Opioid Symptom Scale  
Page 2 7: Section 6.2.5:  
(OSS) (from the Symptom 
Distress Scale)4  
 
Page 3 2: Section 6.3.4, 
Post-Surgical Eligibility 
Assessments and Dosing, #2, c  
 Original Text:  
Page 29 : NA 
 
Page 34 : Opioid symptoms 
Scales (OSS) over past 24 
hours 
 Clarification Added :  
Page 29 :  
The Opioid Symptom Scales are 
measurement instruments for documenting the occurrence and severity of each other opioid- related symptom, as in 
CLCT -002 and CLCT-003. 
Page 34 : Opioid symptoms 
Scales (OSS) over past 24 hours 
PI-CAT Scale  
Page  25:  Section 6.1 , Original Text  
Pain Assessments:  Deleted Text  
Pain Assessments  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 75 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 75 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Evaluations of Safety and 
Eligibility , Pain 
Assessment s  
Page 2 5: Section 6.2.1 
Categorical Pain Intensity 
Scale (PI -CAT)   
Page 61: Appendix 13.1 ‚Ä¶ categorical  pain intensity 
scale, or PI -CAT (which is 
called a ‚ÄúPain Severity Scale‚Äù 
in the patient diary).  Only patients with moderate or severe pain ratings (2 or 3) are 
eligible for the trial.  ‚Ä¶ categorical pain intensity 
scale, or PI-CAT (which is called 
a ‚ÄúPain Severity Scale‚Äù in the 
patient diary).  Only patients 
with moderate or severe pain 
ratings (2 or 3)‚Ä¶   
 
Section 6.2.1 Updated  
‚Ä¶(called ‚ÄúPain‚Äù in the Clinic 
Diary)  
Adverse Event Reporting 
of Opioid ‚Äìrelated Events  
Page 8 : Section 1.3: Study 
Design, Paragraph  13 
Page  25:  Section 6.1, 
Evaluati
ons of Safety and 
Eligibility, Clinical Adverse 
Event Assessment  
 Original Text:  
Section 1.3: Study Design 
The Investigator will rate the 
severity
 of these other (i.e., not 
opioid- related) side effects on 
a 3-category severity scale  
 Section 6.1: A dverse event
  
assessment:   
All adverse events except for those evalua
ted by the patient 
on the NIS, RVI and OSS will be recorded by the Study Coordinator or designee in the 
electronic case report form 
(eCRF) according to Section 9.1 of this protocol. Updated Text:  
Section 1.3: Study Design 
The Investigator will rate the severity of all these other (i.e., 
not opioid- related) side effects 
on a 3- category severity scale  
 
Section 6.1: Clinical adverse 
event 
assessment:   
All adverse events except for 
those evaluated by the patient on 
the NIS, RVI and OSS will be 
recorded by the Study 
Coordinator or designee in the electronic case report form (eCRF) according to Section 9.1 of this protocol.  
Adverse Event Reporting 
of Opioid ‚Äìrelated Events  
Page 2 7: Section 6.2.8, 
Patients Reports of Adverse 
Events (Elicited and 
Volunteered.)  Original Text:  Section 6.2.8   
The Investigator will rate each 
non-opioid- related side effect 
on a 1-3 scale (mild, moderate, 
severe)‚Ä¶  
To avoid duplication of AE data entry
, the following 
opioid- related adverse events 
will not be reported as AEs during the primary 48-hour treatment evaluation period: nausea, retching and vomiting (which are measured as endpoints on the NIS and RVI) 
and dizziness, drowsiness, 
constipation, difficulty Deleted Text: Section 6.2.8  
The Investigator will rate each non-opioid- related  side effect on 
a 1-3 scale (mild, moderate, 
severe)‚Ä¶  
To avoid duplication of AE data 
entry, the following opioid-
related adverse events will not be 
reported as AEs during the 
primary 48-hour treatment 
evaluation period: nausea, 
retching and vomiting (which are 
measured as endpoints on the 
NIS and RVI) and di zziness, 
drowsiness, constipation, 
difficulty voiding, confusion, 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 76 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 76 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
voiding, confusion, headache, 
itch, difficulty concentrating, 
and dry mouth (which are 9 other opioid- related side 
effects measured on the OSS). Observed and reported 
episodes of retching will be  
entered on the Adverse Events 
page of the eCRF
.  headache, itch, difficulty 
concentrating, and dry mouth 
(which are 9 other opioid- related 
side effects measured on the 
OSS). Observed and reported 
episodes of retching will be 
entered on the Adverse Events 
page of the eCRF .  
Adverse Event Reporting 
and Opioid Symptoms  
 
Page 48, Section 9.1.1 
Definitio
n of Adverse Event  
 Original Text  
Because nausea, retching and 
vomiting are measured as endpoints on the NIS, WNS and RVI and because 9 other opioid- related symptoms 
(dizziness, drowsiness, 
constipation, difficulty voiding, 
etc.) are measured on the OSS as secondary endpoints, these 12 opi oid-related symptoms 
will not be duplicated 
as AEs.  Deleted Text  
Because nausea, retching and 
vomiting are measured as 
endpoints on the NIS, WNS and 
RVI and because 9 other opioid-
related symptoms (dizziness, 
drowsiness, constipation, 
difficulty voiding, etc.) are 
measured on the OSS as 
secondary endpoints, these 12 
opioid-related symptoms will not 
be duplicated as AEs . 
Adverse Event Reporting 
and Opioid Symptoms  
 
Page 50:  Section 9.1.5, 
Treatmen
t Period  Original Text  
Adverse events occurring 
from the initial study drug administration to the follow -
up Visit 3 discharge should be recorded as adverse events in the eCRF.  However, nausea, retching, vomiting, other opioid symptoms (on the OSS) and the usual post-surgical ou tcomes of 
bunionectomy should not be recorded as adverse events.  Deleted Text  
Adverse events occurring from the initial study drug administration to the follow -up 
Visit 3 discharge should be recorded as adverse events in the eCRF.  However, nausea, 
retchin g, vomiting, other opioid 
symptoms (on the OSS) and the 
usual post- surgical outcomes of 
bunionectomy should not be 
recorded as adverse events.  
   
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 77 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 77 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
NPR Scale  
 
Page 2 6, Section 6.2.2, 
Numerical Pain Intensity 
Rating Scale (PI -NRS)   
 
Page 58: Appendix 13.1  Original Text  
Numerical Pain Intensity 
Rating Scale (PI -NRS)   
(called ‚ÄúPain Severity Scale‚Äù 
in the Clinic D
iary)  
Patients will be asked at baseline and
 at every post 
treatment assessment time‚Ä¶  
This is the measurement instrument f
or the co- primary 
analgesia endpoint. 
 Original Text  
Numerical Pain Intensity Rating 
Scale (PI -NRS)   
(called ‚ÄúPain Severity Scale ‚Äù in 
the Clinic Diary)  
The patient s will be asked at 
baseline and at every post 
treatment assessment time ‚Ä¶  
The Numerical Pain Intensity 
Rating  Scal e is the measurement 
instrument for the co- primary 
analgesia endpoint. 
Page 28: Section 6.3.2 
Screening Procedures  Original Text  
Criterion D :  If Criteria A -C 
do not qualify a patient‚Ä¶ ‚Äúclinical judgment‚Äù to admit up to ca. 10% ‚Ä¶. Updated Text  
Criterion D :  If Criteria A -C 
does not qualify a patient ... 
‚Äúclinical judgment‚Äù to admit up to approximately 10% ‚Ä¶. 
Surgical Clarification  
 
Page 32:  Section 6.3.3 
Surgica
l Day (Visit 2)  Original Text  
‚Ä¶and for observation for up 
to 9 hours to observe if the patient develops moderate- to-
severe pain.  During this period, the patient will be instructed how to use the rating scales in the Diary.  
 Added Text  
‚Ä¶and for observation for up to 9 hours to observe if the patient develops moderate- to-severe 
pain after  the PSP is 
discontinued . During this 
period, the patient will be instructed how to use the rating scales in the Diary.  
Page 32:  Section 6.3.4 : 
Post-Surgical Eligibility  Original Text  
During the post -surgical 
period until 10 minutes pre-dosing, patients m ay consume 
non-caffeinated liquids and 
soft foods (no chocolate) served at room temperature.  No other treatment is permitted.    
‚Ä¶ If 9 hours have transpired 
since surg
ery ended and the 
patient does not indicate‚Ä¶  Updated Text  
During the post -surgical peri od 
until 10 minutes pre-dosing, patients may consume non -
caffeinated liquids and soft food 
(no chocolate) served at room 
temperature.   No other 
treatment is permitted.    
‚Ä¶ If 9 hours have transpired since the popliteal sciatic block 
was discontinued ended and the 
patient does not indicate‚Ä¶  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 78 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 78 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Vital Sign Measurements  
 
Page 32:  Section 6.3.4, 
Post-Surg
ical Eligibility  Original Text  
NA Added Text  
Patients are to be in a semi -
recumbent position at least 15 
minutes prior to each scheduled assessment time.
 
Smoking Exclusions  
 
Page 38: Section 6.4 
Concomitant 
Medications  
 Original Text  
Any concomitant medication used (e.g., antihypertensive, contraceptive) including 
cigarettes smoked during the study must be entered into the 
eCRF.  Deleted Text  
Any concomitant medication used (e.g., antihypertensive, contraceptive) including 
cigarettes smoked during the 
study must be entered into the 
eCRF.  
Page 42, Section 7.3.4  
Key Secondary Endpoints  Original Text  
#2 Percentage of patients without any vomiting over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
 
#3 Percentage of patients without any nau
sea over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 
325 mg 
 
#4 Percentage of patients 
without any nau
sea or 
vomiting over 48 hours, comparing CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 mg
    Updated and Added Text  
#2 Percentage of patients with out 
any vomiting over 48 hours, 
comparing CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 mg  
 
#3 Percentage of patients with out 
any nausea over 48 hours, 
comparing CL-108 5 mg to 
hydrocodone 5 mg/APAP 325 mg 
 
#4 Percentage of patients without any nausea or vomiting 
over 48 hours, comparing CL-108 5 mg to hydrocodone 5 
mg/APAP 325 mg  
 
#5 Percentage of patients with 
Post- Disch
arge Nausea and 
Vomiting (PDNV) over days 3 -7 
 
#6 Number of doses of study medication
 taken over days 3 -7 
 
#7 Number of doses of study medication
 taken per day over 
days 3-7 
   
Labeling Endpoints  
 
Page 4 2-43: 7.4.4 Labeling 
E
ndpoints  Original Text:  
Number 3:  
Patients treated with CL -108 5 
mg exper
ience less nausea Updated Text  
Number 3:  
More pPatients treated with CL -
108 5 mg experience complete 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 79 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 79 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
 than patients treated with a 
comparable product 
containing hydrocodone 5 mg/ acetaminophen 325 mg 
 absence of OINV less nausea  
than patients treated with a comparable product containing hydrocodone 5 mg/ acetaminophen 325 mg 
Added # 5 and #6  
#5: Patients treated with CL -108 
5 mg experience less nausea than p atients treated with a 
comparable product containing hydrocodone 5 mg/acetaminophen 325 mg 
#6: Patients treated with CL -108 
5 mg experience less nausea and vomiting than patients treated with a comparable product containing hydrocodone 5 mg/acetaminophen 325 mg 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 80 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 80 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Page 45: Section 7.4.16  
Safety  
 Original Text  
‚Ä¶nausea, retching, vomiting, 
emetic episodes).   
 Updated Text  
‚Ä¶nausea, retching, vomiting, emetic episodes, sleep 
disturbance, headache).   
 
Page 46: Section 7.4.18, 
Protocol Deviations  Original Text  
‚Ä¶could significantly affect 
efficacy will be excluded‚Ä¶  Updated Text:  
‚Ä¶could significantly affect 
efficacy results (e.g., a missed 
dose of study medication)  will 
be excluded 
Urine Cotinine Test 
Added to the Protocol  
 
Page 6-9: Section 1.3, 
Study Desig
n, Paragraphs 2, 
3 
 
Page 11 : Section 1.8, Study 
Flow Chart: Line for Urine 
Cotinine Added 
 Page 13-18: Section 4.1, 
Visit 1 , 4.2: Vis 
it 2 and 4.4: 
Visit 3  
 
Page 19: Section 5.2, 
Exclusion Cri
teria, #4 
Confounding and Contraindicated Drugs  
 Page 23: Section 5.6.1, 
Investigat
or‚Äôs Reason for 
Withdrawal  
 
Page 25: Section 6.1: 
Evaluation
s of Efficacy and 
Safety  
 Page 3 0: Section 6.3.3:  
Screening
 Procedures (Visit 
1) and 6.3.3: Surgery Day (Visit 2):  
 
 Original Text  
Cotinine n ot included in the 
original protocol . Added Text:  
Section 1.3:  Paragraph 2:  
‚Ä¶collected (for drug screening 
and cotinine  on all patients)‚Ä¶  
 
Section 1.3 Paragraph 3; 
‚Ä¶and urine drug screening tests 
and urine co
tinine test  will be 
performed  
Section 4.1, 4.2 and 4.4: 
‚Ä¶and urine cotinine test will be 
perform
ed‚Ä¶ 
 
Section 5.2 :  
‚Ä¶oxycodone, cotinine  at 
s
creening‚Ä¶. 
 
Section 5.6: 
‚Ä¶pregnancy test, cotinine t est, 
or drug screening‚Ä¶ 
 
Section 6.1 
Cotinine Test:   A urine cotinine 
test will be performed on each 
patient at the Screening Visit 
and on the morning before 
surgery. A positive result will 
exclude the patient from participating in the trial. A 
urine cotinine test will also be 
performed at Visit 3.  A positive 
result will indicate that the 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 81 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 81 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
 
 patient used nicotine during the 
trial.  
 
Section 6.3.2 and 6.3.3 
‚Ä¢ Urine cotinine test ‚Ä¶ 
General Updates   General grammatical errors were 
updated throughout the 
document . 
   
Page 6: Section 1.3:  Study 
Design  
 Original Text:  
 
Visit 2 . After sedation  
(midazolam and/or propofol) is achieved, regional 
anesthesia will  be established 
with a  popliteal sciatic nerve 
block (PSB) using ropivacaine initially, then mepivacaine, 
after which patients will 
undergo primary‚Ä¶  Updated Text:  
 
Visit 2 . After sedation  
(midazolam and/or propofol) is 
achieved, regional anesthesia 
will b e established with a 
popliteal sciatic nerve block 
(PSB), using ropivacaine, initially 
then mepivacaine,  after which 
patients will undergo primary‚Ä¶ 
Page 19: Section 5.2:  
Exclusion Criteria: #3: 
Drug Allergy  
 Original Text:  
 
‚Ä¶NSAID (such as ibuprofen 
or as pirin), midazolam, 
propofol or ketorolac‚Ä¶  Added Text:  
 
NSAID (such as ibuprofen or 
aspirin), m
idazolam, propofol, 
mepivacaine, ropi vacaine or 
ketorolac  
Page 31: Section 6.3.3:  
Surgery Day (Visit 2) 
 Original Text:  
 
Postoperative pain will be 
controlled by a continuous 
anesthetic infusion through the 
catheter previously placed 
adjacent to the popliteal sciatic 
nerve.   Mepivacaine 0.5%... 
 
 All use of mepivacaine will be 
discontinued 
at approximately 
3 am.  
 
 Added Text:  
 
Postoperative pain will be 
controlled by
 a continuous 
anesthetic infusion through the 
catheter previously placed 
adjacent to the popliteal sciatic 
nerve.  Two methods of 
continuous anesthetic infusion 
are permitted.  Mepivacaine 
0.5%...  
 
All use of mepivacaine will be 
discontinued 
at approximately 3 
am on the morning following 
surgery.  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 82 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 82 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
 
 
 
Page 31: Section 6.3.3:  
Surgery Day (Visit 2) 
 Original Text:  
 
All use of ketorolac will be 
discontinued at 1:30 am. Added Text:  
 
All use of ketorolac will be 
discontinued at 1:30 am on the 
morning following surgery.  
Page 31: Section 6.3.3:  
Surgery Day (Visit 2) 
 Original Text:  
 New text Added Text:  
 
Alternatively, postoperative pain 
will be cont
rolled by a 
continuous ropivacaine  0.2%  
infusion through the catheter previously placed adjacent to the popliteal sciatic nerve.  Ropivacaine 0.2 % will be 
infused starting at 1 -2 mL per 
hour and titrating the rate of 
infusion as needed up to a maximum rate of 10 mL per hour.  All use of r opivacaine will 
be discontinued at approximately 3 am on the morning following surgery. 
During this continuous infusion 
period, patients may receive 
supplemental analgesia for 
breakthrough pain (patients less 
than 65 years of age and greater 
than 50 kg:  ketorolac 30 mg IM 
or IV every 6 hours as needed with a maximum daily dose of 120 mg; patients greater than or 
equal to 65 years of age or less 
than 50 kg: ketorolac 15 mg IM 
or IV every 6 hours as needed 
with a maximum daily dose of 60 mg).  All use of ket orolac will 
be discontinued at 1:30 am on 
the morning following surgery . 
 
  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 83 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 83 of 86 
 16 Protocol Amendment 2: Table of  Changes  
Section Updated  Original Text/Content  Updated Text/Content  
Title Page and Footers  
Dates and Version #  Original Text  
Version 2.0, June 16, 2017 Updated Text:  
Version 3.0, 13 August 2017 
Clarifying that positive 
urine drug screen will 
result is screen failure of 
subject . 
 
Page 11: Section 1.8,  
Study Flow Chart: Urine 
Drug Screen Footnote  Original Text : None  Added Text:  
11 A positive urine drug screen 
will exclude the patient from 
participating in the study. 
Clarifying to awake 
subjects for scheduled 
dosing.  
 
Page 7  and 8,  Section 1.3,  
Study D
esign  
 
Page 16, Section 4.2, 
Paragraph 14,  
V
isit 2  
 
Page 35, Section 6.3.4, 
Post-Surgical
 Eligibility 
Assessment and Dosing,  
 
Page 37, Section 6.3.6, #6b 
Study Times: 12 Hours 
Post-Initial Dose through 48 
Hours  Original Text :  
None Added Text :   
Subjects should be awoken for 
dosing, as needed to remain on the dosing schedule.  
Clarifying % Lidocaine  
Page 14, Section 4.2 
Visit 2  
 
Page 30, Section 6.3.3  
Surgery Day (Visit 2)  Original Text  
Section 4.2: ‚Ä¶ short- acting 
lidocaine 1% (plain).  
 
Section 6.3.3, Paragraph 4: 
inject appr
oximately 5 mL 
lidocaine 2% (plain) locally ‚Ä¶ 
 
 
Section 6.3.3, Paragraph 5 : 
‚Ä¶ using short- acting lidocaine 
2% (plain, without 
epinephrine)‚Ä¶  
 Updated Text  
Section 4.2: ‚Ä¶ short- acting 
lidocaine 1% or 2%  (plain).  
 Section 6.3.3, Paragraph 4: 
inject appr
oximately 5 mL 
lidocaine 1% or  2% (plain) 
locally‚Ä¶  
 
Section 6.3.3 Paragraph 5:  ‚Ä¶ 
using short- a
cting lidocaine 1% 
or 2% (plain, without 
epinephrine)‚Ä¶ 
Page 28, Section 6.3.2,  Original Text  Updated Text  
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 84 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 84 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
Screening Procedures (Visit 
1), Criterion B  Criterion B : If a patient has at 
least one of the following 5 
responses to Questions 26-27, 30, 
32-34, or 39 (relating to motion 
sickness) on the NPQ  Criterion B : If a patient has at 
least one of the following 5 
responses to Questions 26 -27, 
30, 32-34, or 39 (relating to 
motion sickness) on the NPQ  
Page 30, Section 6.3.3,  
Surgery Day (Visit 2)  Original Text  
Alternatively, postoperative pain will be controlled by a 
continuous ropivacaine 0.2% 
infusion
 through the catheter 
previously placed adjacent to 
the popliteal sciatic nerve.  
Ropivacaine 0.2 % will be 
infused starting at 1 -2 mL per 
hour and titrating the rate of infusion as needed up to a 
maximum rate of 10 mL per hour. 
 
 Updated Text  
Alternatively, postoperative pain will be controlled by a 
continuous ropivacaine 0.2% 
infusion through the catheter 
previously placed adjacent to 
the popliteal sciatic nerve.  via 
PSB catheter on a PCA pump at 
a continuous rate of 1 ml/hr.  
Up to two, 3 ml boluses of 
Ropivacaine 0.2% may be given 
per hr.  If pain is not adequately 
controlled after two boluses, 
infusion may be increased b y 
2ml/hr.  Ropivacaine 0.2 % will 
be infused starting at 1 -2 mL 
per hour and titrating the rate 
of infusion as needed up to a 
maximum rate of 10 mL per 
hour.   
Page 42, Section 7.3.4  
Key Secondary Endpoints  Original Text  
#2 Percentage of patients 
without any vomiting over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
 
#3 Percentage of patients 
without any nau 
sea over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg 
 
#4 Percentage of patients 
without any nausea or 
vomiting  over 48 hours, 
comparing CL -108 5 mg 
to hydrocodone 5 
mg/APAP 325 mg     Updated and Added Text  
#2 Percentage of patients without any vomiting over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg  
 
#3 Percentage of patients 
without any naus ea over 48 
hours, comparing CL -108 5 mg 
to hydrocodone 5 mg/APAP 325 mg 
 
#4 Percentage of patients without any nausea or vomiting 
over 48 hours, comparing CL-108 5 mg to hydrocodone 5 
mg/APAP 325 mg  
 
#5 Percentage of patients with 
Post-Dischar
ge Nausea an d 
Vomiting (PDNV) over days 3 -7 
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 85 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 85 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
#6 Number of doses of study 
medication taken over days 3 -7 
 
#7 Number of doses of study 
medication
 taken per day over 
days 3-7 
   
Page 43, Section 7.4.4  
Labeling Endpoints Original Text  
No #7-#9 Added Text  
#7. Patients treated with CL -108 
5 mg experience less nausea and 
vomiting after discharge 
following surgery than patients 
treated with a comparable 
product containing hydrocodone 
5 mg/acetaminophen 325 mg  
 
#8 Patients treated with CL -108 
5 mg take 
more doses over days 
3-7 and have greater reduction 
in pain and less OINV after 
discharge following surgery 
than patients treated with a comparable product containing 
hydrocodone 5 mg/ 
acetaminophen 325 mg  
 
#9.  Patients treated with CL -
108 5 mg take more doses each 
day over days 3 -7 and have 
greater reduction in pain and less OINV after discharge 
following surgery than patients treated with a comparable 
product containing 
hydrocodone 5 mg/ 
acetaminophen 325  mg. 
Page 46, Section 7.4.17  
Interim Analysis  Original Text  
No Interim Analysis is 
planned.  Added Text  
No Interim Analysis is 
planned.  An independent Data 
Monitoring Committee (DMC) 
will meet to review efficacy and 
safety endpoints. The DMC will 
operate under a charter and will 
make recommendations to the sponsor. An interim analysis 
will be performed by the DMC 
after approximately 66% of the 
subjects have completed the 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 86 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
CHARLESTON LABORATORIES, INC. 
Protocol No. CLCT-018 
 
17 August 2017 CONFIDENTIA L P age 86 of 86 
 Section Updated  Original Text/Content  Updated Text/Content  
300-subject study and there is 
adequate representation from 
each of the investigative sites (i.e., approximately 30 
completed subjects per site).   If 
it is judged impossible to achieve this deminimis 
representation at a par ticular 
site or sites, the interim analysis will be conducted on the total 
number of subjects completed 
(i.e., approximately 200 
subjects). Since the DMC will 
review efficacy data, formal 
sequential boundaries for efficacy and futility will be 
declared in the DMC‚Äôs 
Statistical  Analysis Plan.  
Page 62 , Section 13.4  
Appendix 3, Nausea Prone Questionnaire Original Text  
#20, Responses ‚ÄúYes‚Äù and ‚ÄúNo‚Äù  
 Updated Text  
#20, Responses, ‚ÄúYes‚Äù, ‚ÄúNo‚Äù and ‚Äú NA‚Äù 
Page 71, Appendix 14 
Protocol Agreement  Original Text  
Version 2.0  Updated Text  
Version 3.0 
 
 
Charleston Laboratories, Inc. 
Protocol Number: CLCT-018
Clinical Study Report, Final 
09-Nov-2018
Confidential
Page 87 of 87
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________